



JAWAHARLAL INSTITUTE OF POST GRADUATE MEDICAL EDUCATION &
RESEARCH
(JIPMER)

GOVERNMENT OF INDIA
(An Institution of National Importance under Ministry of Health & Family Welfare)
Puducherry-605006



OPEN E-TENDER FOR ENTERING INTO A RATE CONTRACT FOR SUPPLY OF DRUGS, DISINFECTANT FLUIDS, SURGICAL DRESSINGS AND MISC. ITEMS FOR JIPMER, PUDUCHERRY.

@@@

TENDER I (2020 – 21)

(1st December 2020 to 30th November 2021)

TENDER DOCUMENT

| | |
|--|--------------------------------|
| Commencement of online submission | 20-10-2020 on 06.00 PM |
| Last date and time for online submission | 04-11-2020 up to 12.00 NOON |
| Cost of the Tender Processing Fee | Rs.590/- (Inclusive of 18%GST) |

**DEPARTMENT OF PHARMACY
JIPMER
Puducherry. 605006**

Telephone. No. 0413 –2296617 Fax: 0413 – 2271269

[Email: jipmer.pharmacy@gmail.com](mailto:jipmer.pharmacy@gmail.com)

CONTENTS

| S. No. | Description | Page No. |
|--------|--|----------|
| 1 | Notice Inviting Tender | 3 |
| 2 | Earnest Money Deposit (EMD) | 4&28 |
| 3 | Eligibility Criteria | 28 |
| 4 | Eligibility Criteria for selecting renal transplant drugs | 30 |
| 5 | Eligibility Criteria for selecting Biologicals | 31 |
| 6 | Security Deposit | 31 |
| 7 | Techno-Commercial Bid | 32 |
| 8 | Price Bid | 34 |
| 9 | Special Conditions | 40 |
| 10 | Supply Conditions | 42 |
| 11 | Delivery Conditions | 44 |
| 12 | Packaging | 45 |
| 13 | Other Conditions | 46 |
| 14 | Quality | 48 |
| 15 | Penalty | 49 |
| 16 | Force Majeure | 49 |
| 17 | Blacklisting | 50 |
| 18 | Requirement of Godown | 50 |
| 19 | Points to remember | 51 |
| 20 | Tender Form (Annexure 1) | 53 |
| 21 | Declaration of the bidder (Annexure 2) | 55 |
| 22 | Affidavit (Annexure 3) | 56 |
| 23 | Check List | 57 |
| 24 | Appendix -A Self-certification format for claiming purchase preference under the “Public Procurement preference to Make in India” order | 58 |

**JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND
RESEARCH
PUDUCHERRY – 6
(Institution of National Importance under the Ministry of Health & Family Welfare,
Govt. of India)**

DEPARTMENT OF PHARMACY

No.Pur.8 (1)/2020-21/TENDER-I

Dated: 09.10.2020

NOTICE INVITING e-TENDER (e-NIT)

Sub: Entering into a Rate Contract for the Supply of Drugs, Disinfectant Fluids and Surgical Dressing Items for the year 2020-21

Open E- tenders are invited from eligible and qualified tenderers for entering into a rate contract for the supply of the Drugs, Disinfectant Fluids and Surgical Dressing Items to the Department of Pharmacy from **1st December 2020 to 30th November 2021**.

1. Scope of work : Annual contract for supply of Drugs, Disinfectant Fluids and Surgical Dressing Items and Misc. Items to Department of Pharmacy.
2. Value of tender : Annual Approximate Cost Rs.30 crores
3. Duration of the contract : One year
(1st December 2020 to 30th November 2021) And may be extended further up to three months with same rates, terms & conditions. (So, rates quoted should be valid for 15 months)
4. Address for Communication : The Head,
Dept. of Pharmacy
Pharmacy Block First Floor
JIPMER, Puducherry-605006.
Email: jipmer.pharmacy@gmail.com
5. Contact official : Chief Pharmacist,
Dept. of Pharmacy
Pharmacy Block First Floor
JIPMER Puducherry. 605006

6. Phone Number :0413-2296617/0413-2271269

7. Tender timelines:

- i. Last date for receipt of pre-bid queries: **12.00 NOON** on **15-10-2020**
- ii. Pre-bid queries can be made before pre-bid meeting through e-mail jipmer.pharmacy@gmail.com
- iii. Pre-bid meeting date, time and venue : **02.30 PM** on **16-10-2020**
Purchase section, Administrative Block, JIPMER, Puducherry
- iv. Date and time of start of Bid submission : **06.00 PM** on **20-10-2020**
- v. Closing date & time for submission of online bids: **12.00 NOON.** on **04-11-2020**
- vi. Time and date of online opening of Technical Bids: **02.30 PM** on **05-11-2020**

8. Earnest Money Deposit : **Rs.50,000/-** and Tender Processing fee: **Rs.590/-** (Inclusive of 18% GST) to be paid through SBI collect only. The EMD shall be returned without interest to the non-successful tenderers after acceptance of award of contract by the successful bidder. Tender Processing fee will not be refunded under any circumstance. **Bidders who had paid tender fee and EMD in full for the tender Pur.8 (1)/2020-21/Tender I dt 10.06.2020 which was cancelled need not pay again provided they have not asked for refund of the EMD. But the bidder should mention in the tender form that they would like to adjust the tender fee and EMD that they had paid for the aforesaid cancelled tender with the corresponding requirements of this tender and must upload the same tender fee receipt and EMD payment receipt that was uploaded in the aforesaid tender once again during bid submission for this tender.**

9. Interested bidders are advised to download the complete Tender Enquiry document from the websites www.jipmer.edu.in or <https://eprocure.gov.in/eprocure/app> for complete details.

10. The prospective bidders must register with the E-procurement system of <https://eprocure.gov.in/eprocure/app>. Special Instructions to the bidders for the e-submission of the bids online through this eProcurement Portal on completion of the registration process is given in <https://eprocure.gov.in/eprocure/app>, The bidders will be provided user ID and password upon enrolment. In order to

submit the bids electronically, bidders are required to have a valid Class 3 Digital Signature Certificate (signing and encryption/ decryption certificates).

11. Bidders are requested to read the bidders help document on e-tender web site link before proceeding for bidding.
12. Post receipt of User ID & Password, bidders can log on for downloading & uploading tender document.
13. The bidders shall submit the required EMD (as per-tender conditions clause 3, 4) through SBI collect only before the due date and time mentioned above.
14. The online submission of tender(s) can only be done through <https://eprocure.gov.in/eprocure/app>
15. Bidders shall ensure that their tender(s), complete in all respects, are submitted online through <https://eprocure.gov.in/eprocure/app>-portal (as described above) only.
16. Earnest Money Deposit (EMD) payment receipts must be scanned and uploaded on the eprocurement portal while submitting the bid online.
17. Prospective bidders are advised to browse the above mentioned websites i.e., www.jipmer.edu.in and <https://eprocure.gov.in/eprocure/app> regularly before submission of their bids, as any further amendments, addendums or corrigenda will be published in these websites only.

Officer in Charge
Purchase Section,
For
Director,
JIPMER, Puducherry

**E-Tender for Supply of Drugs, Disinfectant Fluids and Surgical Dressing Items to
Department of Pharmacy, JIPMER, Puducherry, from 1st December 2020 to 30th
November 2021**

I. LIST OF ITEMS REQUIRED WITH ESTIMATED ANNUAL REQUIREMENT

| TENDER- I 2020 - 21 LIST OF DRUGS & MISCELLANEOUS ITEMS FOR THE YEAR 2020 - 21 1st DECEMBER 2020 to 30th NOVEMBER 2021 | | | |
|---|---|--|-------------------------------------|
| <u>TABLETS/CAPSULES AND INHALERS</u> | | | |
| Supply in loose packing will not be accepted. Wherever metallic foil pack is mentioned, supply should be made in metallic foil pack on both sides failing which the supply may be rejected. All items should conform strictly to IP/BP/USP standards unless otherwise mentioned. | | | |
| S. No | Nomenclature | Average Requirement for the Tender Period In Units | Rate Should be quoted for each Unit |
| 1 | Acetazolamide 250 mg | 90000 | Tab |
| 2 | Acetylsalicylic acid 150 mg | 3600000 | Tab |
| 3 | Acyclovir 400 mg | 130000 | Tab/Cap |
| 4 | Albendazole 400 mg | 30000 | Tab |
| 5 | Allopurinol 100 mg | 101000 | Tab |
| 6 | Alphacalcidol 0.25 mcg | 175000 | Tab/Cap |
| 7 | Alprazolam 0.5 mg | 110000 | Tab |
| 8 | All trans retinoic acid (ATRA) 10 mg | 7500 | Tab/Cap |
| 9 | Amitriptyline hydrochloride 25 mg | 1750000 | Tab |
| 10 | Amlodipine besylate 5 mg | 5500000 | Tab |
| 11 | Amoxicillin trihydrate 125 mg dispersible | 30000 | Tab |
| 12 | Amoxicillin trihydrate 250 mg | 800000 | Cap |
| 13 | Amoxicillin trihydrate 500 mg | 400000 | Cap |
| 14 | Amoxicillin trihydrate 500 mg with clavulanic acid 125 mg (Metallic foil / Aluminium Blister pack on both sides) | 80000 | Tab |
| 15 | Anti H- Pylori Kit (Pantoprazole (or) Esomeprazole 40 mg+Amoxicillin 750 mg +Clarithromycin 500 mg (each 2 Tabs pack)) | 8000 | KIT |
| 16 | Aprepitant 125 mg /80 mg Kit (125 mg - 1 Cap + 80 mg - 2 Caps) | 6000 | KIT (3 Caps) |
| 17 | Aripiprazole 5 mg | 40000 | Tab |
| 18 | Aripiprazole 20 mg | 40000 | Tab |

| | | | |
|----|--|---------|---------|
| 19 | Atenolol 25 mg | 4350000 | Tab |
| 20 | Atorvastatin 10 mg | 6500000 | Tab |
| 21 | Atorvastatin 40 mg | 3000000 | Tab |
| 22 | Azathioprine 50 mg | 605000 | Tab |
| 23 | Azithromycin 100 mg Dispersible tabs | 8000 | Tab |
| 24 | Azithromycin 500 mg | 50000 | Tab |
| 25 | Baclofen 10 mg | 200000 | Tab |
| 26 | Beclomethasone dipropionate 200 mcg rota caps | 3500000 | Cap |
| 27 | Bisacodyl 5 mg Gastro resistant Tablets | 720000 | Tab |
| 28 | Calcium 250 mg + Vitamin D3 125 IU | 7500000 | Tab |
| 29 | Calcium 500 mg + Vitamin D3 250 IU | 9000000 | Tab |
| 30 | Capecitabine 500 mg | 225000 | Tab/Cap |
| 31 | Carbamazepine 200 mg | 2525000 | Tab |
| 32 | Carbimazole 5 mg | 505000 | Tab |
| 33 | Cetirizine 10 mg | 1600000 | Tab |
| 34 | Chlorambucil 5 mg | 1400 | Tab/Cap |
| 35 | Chlorpheniramine maleate 4 mg | 1100000 | Tab |
| 36 | Chlorpromazine hydrochloride 100 mg | 300000 | Tab |
| 37 | Cinnarizine 25 mg | 15000 | Tab |
| 38 | Ciprofloxacin 500 mg | 400000 | Tab |
| 39 | Clarithromycin 250 mg | 3500 | Tab |
| 40 | Clobazam 10 mg | 2100 | Tab |
| 41 | Clomiphene citrate 100 mg | 3500 | Tab |
| 42 | Clomipramine 25 mg | 4000 | Tab |
| 43 | Clonazepam 0.5 mg | 800000 | Tab |
| 44 | Clonidine 0.1mg | 300000 | Tab |
| 45 | Clopidogrel 75 mg | 2200000 | Tab |
| 46 | Cloxacillin Sodium 250 mg | 780000 | Cap |
| 47 | Cloxacillin Sodium 500 mg | 500000 | Cap |
| 48 | Clozapine 25 mg | 30000 | Tab |
| 49 | Clozapine 100 mg | 30000 | Tab |
| 50 | Cotrimoxazole 80:400 mg | 100000 | Tab |
| 51 | Cotrimoxazole 160:800 mg | 110000 | Tab |
| 52 | Cyclophosphamide 50 mg | 30000 | Tab |
| 53 | Cyclosporine 25 mg | 50000 | Cap |
| 54 | Cyclosporine 50 mg | 300000 | Cap |
| 55 | Daclatasvir 60 mg | 9000 | Tab |
| 56 | Danazol 100 mg | 20000 | Tab/Cap |
| 57 | Deferasirox 500 mg | 1400 | Tab |
| 58 | Deferiprone 500 mg | 42000 | Tab |
| 59 | Dexamethasone 4 mg | 110000 | Tab |
| 60 | Diazepam 5 mg | 240000 | Tab |
| 61 | Diclofenac Sodium 50 mg Gastro resistant Tablets | 1500000 | Tab |
| 62 | Dicyclomine hydrochloride 20 mg | 40000 | Tab |
| 63 | Diethylcarbamazine citrate 100 mg | 30000 | Tab |

| | | | |
|-----|---|---------|---------|
| 64 | Digoxin 0.25 mg | 450000 | Tab |
| 65 | Diltiazem 30 mg | 20000 | Tab |
| 66 | Disulfiram 250 mg | 8000 | Tab |
| 67 | Doxycycline 100 mg | 200000 | Cap |
| 68 | Dydrogesterone 10 mg | 21000 | Tab |
| 69 | D-Penicillamine 250 mg | 51000 | Cap |
| 70 | Eltrombopag 25 mg | 1000 | Tab |
| 71 | Enalapril maleate 5 mg | 7200000 | Tab |
| 72 | Entecavir 0.5 mg | 40000 | Tab |
| 73 | Estradiol Valerate 2mg | 1500 | Tab |
| 74 | Etofylline 231 mg + Theophylline 69 mg Retard /SA | 1100000 | Tab |
| 75 | Etoposide 50 mg | 15000 | Cap |
| 76 | Famotidine 20 mg | 2900000 | Tab |
| 77 | Ferrous sulphate 200 mg | 5500000 | Tab |
| 78 | Finasteride 5 mg | 300000 | Tab |
| 79 | Fluconazole 150 mg | 70000 | Tab/Cap |
| 80 | Flucytosine 500 mg | 12000 | Tab |
| 81 | Fluoxetine hydrochloride 20 mg | 400000 | Tab/Cap |
| 82 | Folic acid 5 mg | 4000000 | Tab |
| 83 | Frusemide 40 mg | 4500000 | Tab |
| 84 | Gabapentin 300 mg | 3600000 | Tab/Cap |
| 85 | Gefitinib 250 mg | 22000 | Tab |
| 86 | Glibenclamide 5 mg | 1000000 | Tab |
| 87 | Glimepiride 2 mg | 3000000 | Tab |
| 88 | Griseofulvin 250 mg | 25000 | Tab |
| 89 | Haloperidol 5 mg | 130000 | Tab |
| 90 | Hydrochlorothiazide 25 mg | 400000 | Tab |
| 91 | Hydroxychloroquine 200 mg | 1300000 | Tab |
| 92 | Hydroxyurea 500 mg | 45000 | Tab |
| 93 | Ibuprofen 400 mg sugar/film coated | 22000 | Tab |
| 94 | Imatinib Mesylate 400 mg | 125000 | Tab/Cap |
| 95 | Indomethacin 25 mg | 350000 | Tab/Cap |
| 96 | Indomethacin SR 75 mg | 60000 | Tab/Cap |
| 97 | Iron capsules each containing minimum of iron equivalent to 60 mg + Folic acid 0.2 mg | 50000 | Tab/Cap |
| 98 | Isosorbide mononitrate 10 mg | 4500000 | Tab |
| 99 | Isosorbide dinitrate 10 mg | 800000 | Tab |
| 100 | Isotretinoin 20 mg | 30000 | Tab/Cap |
| 101 | Isotretinoin 25 mg | 36000 | Cap |
| 102 | Itraconazole 100 mg | 9000 | Cap |
| 103 | Labetalol 100 mg | 45000 | Tab |
| 104 | Lamivudine 100 mg | 15000 | Tab |
| 105 | Ledipasvir 90 mg+Sofosbuvir 400 mg | 7560 | Tab |
| 106 | Leflunomide 10 mg | 600000 | Tab |
| 107 | Lenalidomide 5 mg | 15000 | Cap |

| | | | |
|-----|---|---------------|---------|
| 108 | Lenalidomide 10 mg | 26000 | Cap |
| 109 | Letrozole 2.5 mg | 225000 | Tab |
| 110 | Levetiracetam 500 mg | 250000 | Tab |
| 111 | Levodopa 100 mg + Carbidopa 10 mg | 500000 | Tab |
| 112 | Levodopa 275 mg CR | 3000 | Tab |
| 113 | Levofloxacin 500 mg | 15000 | Tab |
| 114 | Levosulpiride 25 mg | 40000 | Tab |
| 115 | Linezolid 600 mg | 15000 | Tab |
| 116 | Lithium carbonate 300 mg | 350000 | Tab |
| 117 | Lorazepam 2 mg | 175000 | Tab |
| 118 | Losartan 25 mg | 2550000 | Tab |
| 119 | Medical Abortion Kit (Mifepristone 200 mg 1 Tab + Misoprostol 200 mcg 4 Tab) | 140 | Kit |
| 120 | Medroxyprogesterone acetate 10mg | 75000 | Tab |
| 121 | Melphalan 5 mg | 350 | Tab |
| 122 | Mercaptopurine 50 mg | 75000 | Tab |
| 123 | Mesalamine 1.2 gm | 110000 | Tab |
| 124 | Metformin hydrochloride 500 mg | 15000000 | Tab |
| 125 | Methotrexate 2.5 mg | 950000 | Tab |
| 126 | Methyldopa 250 mg | 60000 | Tab |
| 127 | Metoclopramide 10 mg | 450000 | Tab |
| 128 | Metronidazole 400 mg sugar/filmcoated | 350000 | Tab |
| 129 | Misoprostol 25 mcg | 20000 | Tab |
| 130 | Misoprostol 200 mcg | 26000 | Tab |
| 131 | Mycophenolate Mofetil 250 mg | 110000 | Tab/Cap |
| 132 | Mycophenolate Mofetil 500 mg | 650000 | Tab/Cap |
| 133 | Nifedipine 10 mg | 20000 | Tab/Cap |
| 134 | Nitrofurantoin SR 100 mg | 45000 | Tab |
| 135 | Olanzapine 5 mg | 75000 | Tab |
| 136 | Olanzapine 10 mg | 150000 | Tab |
| 137 | Omeprazole 20 mg | 15000000 | Cap |
| 138 | Ondansetron 8 mg | 475000 | Tab |
| 139 | Oseltamivir 30 mg | 6000 | Tab/Cap |
| 140 | Oseltamivir 75 mg | 60000 | Tab/Cap |
| 141 | Oxybutynin 2.5 mg | 350000 | Tab |
| 142 | Pancreatic Enzymes Gastro resistant Tab/Cap containing Lipase 10000 IU | 45000 | Tab/Cap |
| 143 | Paracetamol 500 mg | 7500000 | Tab |
| 144 | Paraformaldehyde 1gm | 30000 | Tab |
| 145 | Phenobarbitone 60 mg | 250000 | Tab |
| 146 | Phenoxymethyl penicillin 125 mg (in metallic foil pack on both sides) | 1000000 | Tab |
| 147 | Phenoxymethyl penicillin 250 mg (in metallic foil pack on both sides) | 1600000 | Tab |

| | | | |
|-----|--|---------------|---------|
| 148 | Phenytoin sodium 100 mg | 2175000 | Tab |
| 149 | Pioglitazone 15 mg | 100000 | Tab |
| 150 | Pomalidomide 1 mg | 1400 | Cap |
| 151 | Pomalidomide 2 mg | 7000 | Cap |
| 152 | Pomalidomide 4 mg | 2100 | Cap |
| 153 | Praziquantel 600 mg | 420 | Tab |
| 154 | Prazosin 1mg | 200000 | Tab |
| 155 | Prednisolone 5 mg | 1100000 | Tab |
| 156 | Prednisolone 10 mg | 1300000 | Tab |
| 157 | Procarbazine 50 mg | 5000 | Tab/Cap |
| 158 | Propranolol hydrochloride 40 mg | 525000 | Tab |
| 159 | Pyridostigmine bromide 60 mg | 175000 | Tab |
| 160 | Ribavirin 200 mg | 12000 | Cap |
| 161 | Rifaximine 550 mg | 225000 | Tab |
| 162 | Risperidone 2 mg | 1175000 | Tab |
| 163 | Salbutamol 4 mg | 75000 | Tab |
| 164 | Salbutamol Rota cap 200 mcg | 3050000 | Cap |
| 165 | Sertraline 50 mg | 7200 | Tab |
| 166 | Sirolimus 1 mg | 2800 | Tab |
| 167 | Sitagliptin 100 mg | 75000 | Tab |
| 168 | Sodium bicarbonate 500 mg | 1850000 | Tab |
| 169 | Sodium Valproate 200 mg Gastro resistant Tablets (Metallic foil pack on both sides) | 4350000 | Tab |
| 170 | Sofosbuvir 400 MG | 9000 | Tab |
| 171 | Sofosbuvir 400 MG+Velpatasvir 100 MG | 4000 | Tab |
| 172 | Sorafenib 200 mg | 30000 | Tab |
| 173 | Spirolactone 25 mg | 1450000 | Tab |
| 174 | Sulfasalazine 500 mg | 1250000 | Tab |
| 175 | Tacrolimus 0.25 mg | 7000 | Cap |
| 176 | Tacrolimus 0.5 mg | 70000 | Cap |
| 177 | Tacrolimus 1 mg | 100000 | Cap |
| 178 | Tacrolimus 2 mg | 175000 | Cap |
| 179 | Tamoxifen Citrate 10 mg | 275000 | Tab |
| 180 | Tamsulosin 0.4 mg (Extended release) | 650000 | Cap |
| 181 | Tenofovir Disoproxil Fumarate 300 mg | 125000 | Tab |
| 182 | Thalidomide 100 mg | 15000 | Tab/Cap |
| 183 | Thyroxine sodium 0.025 mg (30 Tabs.in Amber Coloured bottle) | 500000 | Tab |
| 184 | Thyroxine sodium 0.05 mg (30 Tabs.in Amber Coloured Bottle) | 900000 | Tab |
| 185 | Thyroxine sodium 0.1 mg (30 Tabs.in Amber Coloured bottle) | 1025000 | Tab |
| 186 | Tramadol 50 mg | 1200000 | Tab/Cap |
| 187 | Trihexyphenidyl hydrochloride 2 mg | 1250000 | Tab |
| 188 | Ursodeoxycholic acid 300 mg | 100000 | Tab |

| | | | |
|-----|---|---------|---------|
| 189 | Valganciclovir 450 mg | 25000 | Tab |
| 190 | Verapamil 40 mg | 1400 | Tab |
| 191 | Vitamin A 50000 IU | 15000 | Tab/Cap |
| 192 | Vitamin B Complex NFI Vitamin B1 IP 2 mg Vitamin B2 IP 2 mg Vitamin B6 IP 0.5mg Niacinamide IP 25 mg Calcium pantothenate IP 1 mg | 7500000 | Tab |
| 193 | Vitamin B6 HCl 10 mg | 125000 | Tab |
| 194 | Vitamin B6 HCl 50 mg | 175000 | Tab |
| 195 | Vitamin C (Ascorbic acid) 100 mg | 1100000 | Tab/Cap |
| 196 | Vitamin D ₃ 60000 IU (Cholecalciferol) | 10000 | Tab/Cap |
| 197 | Voriconazole 200 mg | 30000 | Tab |
| 198 | Warfarin 5 mg | 800000 | Tab |
| 199 | Zinc sulphate 10 mg | 2800 | Tab |

OPHTHALMIC AND ENT PREPARATIONS

Samples of all Ophthalmic drops ENT preparation must reach the Pharmacy Office before the last date.

| | | | |
|-----|--|-------|--------|
| 200 | Acyclovir Eye ointment 3% 5 gm | 250 | Tube |
| 201 | Brimonidine Eye drops in the range of 0.15% to 0.2% 5 ml | 1250 | bottle |
| 202 | Chloramphenicol Eye applicaps 1% | 30000 | Cap |
| 203 | Ciprofloxacin 0.3% eye drops 5 ml | 20000 | bottle |
| 204 | Ciprofloxacin 0.3% eye ointment 5 gm | 15000 | Tube |
| 205 | Ciprofloxacin 0.3%+Dexamethasone 0.1% Eye drops | 10000 | bottle |
| 206 | Cyclopentolate eye drops 1% 5 ml | 2500 | bottle |
| 207 | Dorzolamide 2% eye drops 5 ml | 2000 | bottle |
| 208 | Flurbiprofen Eye drops 0.03% 5 ml | 6000 | bottle |
| 209 | Gatifloxacin 0.3% eye drops 5 ml | 3000 | bottle |
| 210 | Homatropine 2% eye drops 5 ml | 3000 | bottle |
| 211 | Hydroxy propyl methyl cellulose 0.7% eye drops 5 ml | 30000 | bottle |
| 212 | Latanoprost 50mcg eye drops 2.5 ml | 2000 | bottle |
| 213 | Ofloxacin 0.3% eye/ear drops 5 ml | 1000 | bottle |
| 214 | Povidone iodine solution 5% 5ml bottle(Non irritant to eyes) | 2500 | bottle |
| 215 | Povidone iodine solution 10% 5ml bottle(Non irritant to eyes) | 2500 | bottle |
| 216 | Phenylephrine 10% eye drops 5 ml | 700 | bottle |
| 217 | Pilocarpine Eye drops 2% 5 ml | 1000 | bottle |
| 218 | Polyvinylalcohol Eye drops 1.4% 5 ml | 4200 | bottle |
| 219 | Prednisolone Acetate 1 % eye drops 5 ml | 5000 | bottle |
| 220 | Proparacaine Hcl 0.5% eye drops 5 ml | 5000 | bottle |
| 221 | Sodium Chloride 0.65% W/V to 0.8% W/V with preservatives - Nasal Drops | 2000 | bottle |
| 222 | Timolol 0.5% eye drops 5 ml | 5000 | bottle |
| 223 | Tropicamide 1% eye drops 5 ml | 7000 | bottle |
| 224 | Xylometazoline Nasal Drops 0.1% 10 ml | 3000 | bottle |
| 225 | Xylometazoline Nasal Drops 0.05% 10 ml | 2800 | bottle |

PREPARATIONS OF EXTERNAL USE

| | | | |
|-----|---|-------|--------------|
| 226 | Beclomethasone Dipropionate 0.025% cream/ointment 15 gm | 30000 | Tube |
| 227 | Bisacodyl Suppository 10 mg | 700 | Suppository |
| 228 | Chlorhexidine gluconate 0.2% mouth rinse/Mouthwash 100 ml | 12000 | Bottle |
| 229 | Clotrimazole Cream 1% 15 gm | 30000 | Tube |
| 230 | Clotrimazole 100 mg vaginal tablets (with applicator in a box of 6 tabs) | 13500 | Box(6 Tabs) |
| 231 | Diclofenac suppository 25 mg | 700 | Suppository |
| 232 | Dry powder Inhalation device for salbutamol and beclomethasone rota caps | 9000 | Device |
| 233 | Framycetin sulphate IP 1% Ointment/Cream 30 gm | 6000 | Tube |
| 234 | Hydrocortisone Butyrate cream 1% 15 gm tube | 1500 | Tube |
| 235 | Ipratropium bromide solution 250 mcg/ml. 15 ml | 15000 | Bottle |
| 236 | Lignocaine HCl 2% Jelly/Gel 30 gm | 40000 | Tube |
| 237 | Mupirocin 2% Ointment/Cream 5 gm tube | 20000 | Tube |
| 238 | Paracetamol suppository 250 mg | 4000 | Suppository |
| 239 | Povidone iodine ointment 5% 15 gm | 9500 | Tube |
| 240 | Salbutamol Respiratory solution 5 mg/ml- 15 ml | 20000 | Bottle |
| 241 | Silver Sulphadiazine Cream STERILE IP/USP 1% - 100 gm | 1500 | JAR |
| 242 | Silver Sulphadiazine Cream STERILE IP/USP 1% - 250 gm | 1500 | JAR |

INJECTIONS

Ampoules should be machine sealed. Vials should be fresh and embossed with same mark for a batch. Each pack of ampoules should contain at least 5 metallic files/ampoule cutters. Samples of all intravenous fluids must reach the Pharmacy Office before the last date. Each Pack should not contain more than TEN Ampoules/Vials.

| | | | |
|-----|--|--------------|--------|
| 243 | Actinomycin-D 0.5 mg Vial (Dactinomycin) | 450 | Vial |
| 244 | Activated Factor VII a 1 mg (Recombinant) Vial | 100 | Vial |
| 245 | Acyclovir 250 mg Vial | 1000 | Vial |
| 246 | Acyclovir 500 mg Vial | 5000 | Vial |
| 247 | Adalimumab 40 mg | 280 | PFS |
| 248 | Adenosine 6 mg/ 2 ml - 2ml Amp | 8000 | Amp |
| 249 | Adrenaline tartrate 1:1000 1ml Amp - preservative free for IV Use | 82500 | Amp |
| 250 | Amikacin 500 mg/ 2ml Vial | 51500 | Vial |
| 251 | Amino Acid 10% 100 ml Bottle containing all amino-acid with essential amino acid composition: Isoleucine 10, Leucine 11, Lysine 9, Threonine 6, Tryptophan 3, Valine 14, Phenylalanine & Tyrosine 14, by parte (For Neonatal use) | 600 | Bottle |
| 252 | Amino Acid 10% 200 ml Bottle containing all amino-acid with essential amino acid composition: Isoleucine 10, Leucine 11, Lysine 9, Threonine 6, Tryptophan 3, Valine 14, Phenylalanine & Tyrosine 14, by parte | 5000 | Bottle |
| 253 | Aminophylline 250 mg 10 ml Amp | 300 | Amp |
| 254 | Amiodarone 50 mg/ml - 3 ml Amp | 3450 | Amp |

| | | | |
|-----|--|--------------|------------|
| 255 | Amoxicillin - 1gm + Clavulanic acid 200 mg Vial | 21000 | Vial |
| 256 | Amphotericin B 50mg Vial | 3100 | Vial |
| 257 | Ampicillin 500 mg Vial | 76500 | Vial |
| 258 | Anti-D Rh factor human immunoglobulin Monoclonal 300 mcg Vial/PFS | 700 | Vial/ PFS |
| 259 | Anti-D Rh factor human immunoglobulin Polyclonal (free from HIV) 300 mcg Vial/PFS | 700 | Vial/ PFS |
| 260 | Antihemophilic Factor IX 600 IU Vial | 300 | Vial |
| 261 | Antirabies vaccine vero cells/ Chicken embryo/ Human Diploid Cell 2.5 IU | 1400 | Amp/ Vial |
| 262 | Antisnake venom (polyvalent) serum - lyophilised powder to be made upto 10 ml Vial | 3200 | Vial |
| 263 | Anti-tetanus toxin human immunoglobulin 500 IU Vial | 500 | Vial |
| 264 | Antitetanus toxin human immunoglobulin 1000 IU Vial | 300 | Vial |
| 265 | Antithymocyte globulin 25 mg (Rabbit) Vial | 300 | Vial |
| 266 | Antithymocyte globulin 100 mg (Rabbit) Vial | 150 | Vial |
| 267 | Antithymocyte globulin 250 mg Vial | 1100 | Vial |
| 268 | Arsenic trioxide 1mg /ml 10 ml Vial | 600 | Vial |
| 269 | Artesunate 60 mg Vial | 900 | Vial |
| 270 | Atracurium besylate 25 mg Amp | 22000 | Amp |
| 271 | Atropine sulphate 0.60 mg/ ml 1 ml for IM/ IV use Amp | 19000 | Amp |
| 272 | Atropine sulphate 100 mg/ 100 ml Bottle | 1500 | Bottle |
| 273 | Azacytidine 100 mg Vial | 300 | Vial |
| 274 | Basiliximab 20 mg Vial | 200 | Vial |
| 275 | B C G Vaccine 40 mg Vial Lyophilised (Moscow Strain or Danish 1331 Strain) for intravesical use | 500 | Amp / vial |
| 276 | Bendamustine 100 mg Vial | 900 | Vial |
| 277 | Benzyl Penicillin Sodium 1 Million IU Vial | 30000 | Vial |
| 278 | Beractant 4 ml Vial | 100 | Vial |
| 279 | Beractant 8 ml Vial | 100 | Vial |
| 280 | Bevacizumab 100 mg Amp/ Vial | 60 | Amp / vial |
| 281 | Bevacizumab 400 mg Amp/ Vial | 60 | Amp / vial |
| 282 | Bleomycin 15 IU Vial | 600 | Vial |
| 283 | Bortezomib 2 mg Vial | 1650 | Vial |
| 284 | Botulinum Toxin type A Inj. 50 units Vial | 50 | Vial |
| 285 | Botulinum Toxin type A Inj. 100 units Vial | 100 | Vial |
| 286 | Botulinum Toxin type A Inj. 500 units Vial | 50 | Vial |
| 287 | Bupivacaine Plain 0.5% Preservative free - 20 ml Vial | 8200 | Vial |
| 288 | Bupivacaine 0.5% (heavy) in dextrose 8% - 4ml Amp | 9600 | Amp |
| 289 | Buprenorphine Transdermal Patch 5 mg | 150 | Patch |
| 290 | Caffeine citrate 60 mg Vial | 1000 | Vial |
| 291 | Calcitonin 100 units Amp/vial | 600 | Amp / vial |
| 292 | Calcium gluconate 10% - 10 ml Amp | 47000 | Amp |

| | | | |
|-----|---|---------------|------------|
| 293 | Carboplatin 150 mg Vial | 2160 | Vial |
| 294 | Carboplatin 450 mg Vial | 2040 | Vial |
| 295 | Carboprost tromethamine 125 mcg/ 0.5 ml Amp/vial | 1000 | Amp / vial |
| 296 | Carboprost tromethamine 250 mcg/ 1ml Amp/vial | 1300 | Amp / vial |
| 297 | Cardiplegia solution/equivalent to each ml containing Pot.Chloride 59.65 mg, Mag.Chloride 162.65 mg, Procaine hydrochloride 13.64 mg - 20ml Amp | 1000 | Amp / vial |
| 298 | Carmustine100 mg (BCNU) Vial | 300 | Vial |
| 299 | Caspofungin 70 mg Vial | 120 | Vial |
| 300 | Cefazolin 1gm Vial | 1000 | Vial |
| 301 | Cefepime 500 mg Amp/ Vial | 10000 | Amp / vial |
| 302 | Cefepime 1gm Vial | 19200 | Vial |
| 303 | Cefoperazone 1gm Vial | 18000 | Vial |
| 304 | Cefoperazone sodium 1 gm + Sulbactam 1gm Vial | 58000 | Vial |
| 305 | Cefotaxime sodium 1gm Vial | 10500 | Vial |
| 306 | Ceftazidime 1gm Vial | 21000 | Vial |
| 307 | Ceftriaxone sodium 1gm Vial | 210000 | Vial |
| 308 | Cetorelix 0.25mg | 1000 | Amp / vial |
| 309 | Chlorpheniramine maleate 10 mg/ ml 1ml Amp for IV use | 24000 | Amp |
| 310 | Cholecalciferol 6 Lac units Amp/ Vial | 1500 | Amp / vial |
| 311 | Ciprofloxacin 200 mg for I V use - 100ml - in Polythene Bottle | 17000 | Bottle |
| 312 | Cisatracurium 2mg/ ml Amp/Vial | 600 | Amp / vial |
| 313 | Cisplatin 10 mg/ 10ml or 20ml Vial | 2600 | Vial |
| 314 | Cisplatin 50 mg/ 50ml Vial | 2700 | Vial |
| 315 | Cladribine 10 mg | 100 | Vial |
| 316 | Clindamycin phosphate - 300 mg/ 2 ml Amp | 26500 | Amp |
| 317 | Cloxacillin sodium IP - 500 mg Vial | 96000 | Vial |
| 318 | Daunorubicin 20 mg Vial | 500 | Vial |
| 319 | Colistimethate sodium Powder 1 Million IU/ 10 ml Vial for solution for Injection/ Infusion /Inhalation | 10500 | Vial |
| 320 | Colistimethate sodium Powder 2 Million IU/ 10 ml Vial for solution for Injection/ Infusion/ Inhalation | 16500 | Vial |
| 321 | Cyclophosphamide IP - 200 mg Vial | 3200 | Vial |
| 322 | Cyclophosphamide IP- 500 mg Vial | 6400 | Vial |
| 323 | Cyclophosphamide IP - 1 gm Vial | 3000 | Vial |
| 324 | Cytarbine 100 mg Vial | 3000 | Vial |
| 325 | Cytarbine 1gm Vial | 1550 | Vial |
| 326 | Dacarbazine 100 mg Vial | 1000 | Vial |
| 327 | Dacarbazine 200 mg Vial | 1800 | Vial |
| 328 | Daptomycin 350 mg Vial | 400 | Vial |
| 329 | Daunorubicin 20 mg Vial | 2000 | Vial |
| 330 | Desflurane 240 ml | 100 | Bottle |
| 331 | Dexamethasone sodium phosphate 8 mg/2 ml Vial for IV use | 50000 | Vial |

| | | | |
|-----|--|--------------|------------|
| 332 | Dexmedetomidine HCl 100mcg For IV use (Preservative free) 1ml Amp/ Vial | 4200 | Amp/Vial |
| 333 | Dextrose 50% 25 ml | 1200 | Amp/Vial |
| 334 | Diazepam for IV use 10 mg / 2 ml Amp | 2000 | Amp |
| 335 | Diclofenac Sodium 75 mg / 3 ml Amp | 31000 | Amp |
| 336 | Dicyclomine 20 mg/ 2 ml Amp | 400 | Amp |
| 337 | Digoxin 0.5 mg/ 2 ml 2ml Amp | 1100 | Amp |
| 338 | Diltiazem 5mg Vial for IV use | 500 | Vial |
| 339 | Dinoprostone 0.5 mg Gel in 3 gm Tube | 1600 | Tube |
| 340 | Diphenylhydantoin sodium 100 mg/2 ml Amp for IM,IV use | 82500 | Amp |
| 341 | Diphtheria Antitoxin 10,000 Units Amp/ Vial | 1000 | Amp / vial |
| 342 | Dobutamine HCl 250 mg/ 5 ml Amp for IV use | 5100 | Amp |
| 343 | Docetaxel 20 mg Vial | 4500 | Vial |
| 344 | Docetaxel 80 mg Vial | 4100 | Vial |
| 345 | Dopamine 200 mg/ 5ml Amp | 4600 | Amp |
| 346 | Doripenem 500 mg Vial | 300 | Vial |
| 347 | Doxorubicin 10 mg (Powder form) Vial | 1700 | Vial |
| 348 | Doxorubicin 50 mg (Powder form) Vial | 1800 | Vial |
| 349 | Doxycycline 100 mg | 800 | Amp / vial |
| 350 | Edaravone 1.5 mg/ ml - 20ml Vial | 300 | Vial |
| 351 | Epirubicin 10 mg Vial | 1800 | Vial |
| 352 | Epirubicin 50 mg Vial | 3200 | Vial |
| 353 | Erythropoietin 2000 IU PFS | 29000 | PFS |
| 354 | Erythropoietin 2000 IU Vial | 29000 | Vial |
| 355 | Esmolol 10 mg/ml 10 ml Vial for IV use | 500 | Vial |
| 356 | Ethacridine lactate 100 mg /100 ml Bottle | 600 | Bottle |
| 357 | Etofylline 169.4 mg + Theophylline 50.6 mg/ 2 ml Amp | 5000 | Amp |
| 358 | Etomidate 2mg/ ml 10 ml Vial | 1400 | Amp / vial |
| 359 | Etoposide 100 mg/5 ml Vial | 3300 | Vial |
| 360 | Fat emulsion 20% containing Soyabean oil, Egg phospholipids 100ml | 2000 | Bottle |
| 361 | Fat emulsion 20% containing Soyabean oil, Egg phospholipids 500ml | 5500 | Bottle |
| 362 | Fluconazole 200 mg/ 100 ml in polythene Bottle for IV use | 2900 | Bottle |
| 363 | Fludarabine 50 mg | 200 | Vial |
| 364 | Flumazenil 0.5 mg/ 5ml Amp/Vial | 200 | Amp / Vial |
| 365 | Fluorescein sodium 20% - 3 ml Amp/Vial | 600 | Amp / Vial |
| 366 | 5-Fluorouracil 250 mg/ 5 ml Amp | 10000 | Amp |
| 367 | Fluphenazine decanoate 25 mg/ ml 1ml | 1200 | Amp |
| 368 | r.Follicle stimulating hormone 75 IU Vial/ PFS/ Ampoule | 600 | Vial/ PFS |
| 369 | r.Follicle stimulating hormone 150 IU Vial/PFS/ Ampoule | 1500 | Vial/ PFS |
| 370 | r.Follicle stimulating hormone 300 IU Vial/PFS/ Ampoule | 600 | Vial /PFS |
| 371 | Fomepizole 1.5 gm/ 1.5 ml | 200 | Amp/ Vial |

| | | | |
|-----|---|---------------|-----------|
| 372 | Frusamide 20 mg/ 2 ml Amp | 136000 | Amp |
| 373 | Gancyclovir 500 mg Vial | 200 | Vial |
| 374 | Gemcitabine 200 mg Vial | 2100 | Vial |
| 375 | Gemcitabine 1gm Vial | 1050 | Vial |
| 376 | Gentamicin sulphate 80 mg/ 2 ml Vial | 27000 | Vial |
| 377 | Glucagon Amp | 200 | Amp |
| 378 | Glycopyrrolate 0.2 mg/ ml 1ml Amp | 28200 | Amp |
| 379 | Golimumab 50 mg PFS | 100 | PFS |
| 380 | Granulocyte colony stimulating Factor(G-CSF) - 300 mcg PFS | 7400 | PFS |
| 381 | Granulocyte colony stimulating Factor(G-CSF) - 300 mcg Vial | 7400 | Vial |
| 382 | Growth Hormone 4 mg (Somatropin) with shelf life of at least two weeks after reconstitution | 1000 | Vial/ PFS |
| 383 | Haloperidol 5 mg/ ml 1ml Amp | 3700 | Amp |
| 384 | Human Chorionic Gonadotropin (HCG) 2000 IU | 1000 | Vial/ PFS |
| 385 | Human Chorionic Gonadotropin (HCG) 5000 IU | 1000 | Vial/ PFS |
| 386 | Human Chorionic Gonadotropin (HCG) 10000 IU | 1000 | Vial/ PFS |
| 387 | Heparin sodium 25000 IU/ 5ml Vial | 36000 | Vial |
| 388 | Hepatitis-B Immunoglobulin 100 IU Amp/ Vial | 200 | Amp/ Vial |
| 389 | Hepatitis-B-Vaccine Adult dose 20 mcg 1 ml Amp/ Vial | 500 | Amp/ Vial |
| 390 | Hepatitis-B-Vaccine Adult dose 20 mcg/1 ml-10 ml Vial | 180 | Vial |
| 391 | Human menopausal gonadotropin (HMG) 75 IU Vial/ PFS | 3600 | Vial/ PFS |
| 392 | Human menopausal gonadotropin (HMG) 150 IU Vial/ PFS | 2400 | Vial/ PFS |
| 393 | Human Albumin 5 % 100 ml Bottle | 1000 | Bottle |
| 394 | Human Albumin 20 % 100 ml Bottle | 5300 | Bottle |
| 395 | Human cryoprecipitated anti-haemophilic Factor- VIII Lyophilized monoclonal purified 250 IU Vial | 4200 | Vial |
| 396 | Human cryoprecipitated anti-haemophilic dried Factor-VIII Lyophilised powder (Plasma derived) 250 IU Vial | 4200 | Vial |
| 397 | Human Insulin 70% Isophane + 30% Neutral 40 IU/ml 10ml Vial made by rDNA technology | 120000 | Vial |
| 398 | Human Insulin Isophane (NPH) 40 IU/ml 10 ml Vial made by rDNA technology | 40000 | Vial |
| 399 | Human Insulin Neutral 40 IU/ml 10 ml Vial made by rDNA technology | 40000 | Vial |
| 400 | Human IV Immunoglobulin 5 gm/ 100 ml Bottle | 2600 | Bottle |
| 401 | Human IV Immunoglobulin 10 gm/ 100 ml Bottle | 1200 | Bottle |
| 402 | Human Papilloma Virus (HPV) 0.5ml Vial/ PFS (Quadrivalent) | 500 | Vial/ PFS |
| 403 | Human Rabies immunoglobulin 300 IU in 2 ml | 1200 | Vial/ PFS |
| 404 | Hyaluronidase 1500 IU Amp/ Vial | 1100 | Amp/ vial |
| 405 | Hydralazine hydrochloride 20 mg Amp | 1200 | Amp |
| 406 | Hydrocortisone acetate 100 mg Amp/ Vial | 1200 | Amp/ vial |
| 407 | Hydrocortisone sodium succinate 100 mg Vial | 25000 | Vial |

| | | | |
|-----|---|--------------|--------------|
| 408 | Hyoscine butyl bromide 20 mg/ 1ml for IV use Amp | 10500 | Amp |
| 409 | Ifosfamide 1gm Vial with Mesna 200 mg x 3 Amps | 2300 | Amp/ vial |
| 410 | Inactivated Quadrivalent Influenza vaccine (split Virion) 0.5 ml PFS for 2020-21 Northern hemisphere season as recommended by WHO | 3000 | PFS |
| 411 | Infliximab 100 mg Vial | 100 | Vial |
| 412 | Iohexol/ Iopromide/ Iopamidol 350 mg of Iodine/ ml, 90 ml Bottle | 7000 | Bottle |
| 413 | Iohexol/ Iopromide/ Iopamidol 350 mg of Iodine/ml, 100 ml Bottle | 6200 | Bottle |
| 414 | Irinotecan 100 mg Vial | 850 | Vial |
| 415 | Iron sucrose IV 100 mg/ 5ml Amp/ Vial | 3300 | Amp/ vial |
| 416 | Isoflurane 100 ml Bottle | 2600 | Bottle |
| 417 | Isoprenaline sulphate or hydrochloride 2 mg Amp | 250 | Amp |
| 418 | Ketamine hydrochloride 50 mg/ ml 10 ml Vial | 2700 | Vial |
| 419 | Ketorolac 30 mg/ ml 1 ml for IM, IV use Amp | 60000 | Amp |
| 420 | L Asparaginase 5000 IU Vial | 1200 | Vial |
| 421 | L Asparaginase 10000 IU Vial | 1200 | Vial |
| 422 | Labetalol 20 mg/ 4 ml Amp/ Vial | 8100 | Amp/ vial |
| 423 | Leucovorin calcium 50 mg/ 5 ml Vial | 5000 | Vial |
| 424 | Leuprolide 1 mg Ampoule / Vial/ PFS | 200 | Amp/Vial/PFS |
| 425 | Leuprolide Depot 3.75 mg Amp/ Vial | 2000 | Amp/ vial |
| 426 | Levetiracetam for IV 500 mg/ 5 ml Amp/ Vial | 1000 | Amp/ vial |
| 427 | Levofloxacin Hcl 500 mg/100 ml for IV use in polythene Bottle | 600 | Bottle |
| 428 | Levosimendan 12.5 mg Amp | 500 | Amp |
| 429 | Levothyroxine 100 mcg | 300 | Amp/ vial |
| 430 | Lignocaine 10% spray 50 ml Can | 210 | Can |
| 431 | Lignocaine HCl 2% 30 ml | 21000 | Vial |
| 432 | Lignocaine HCL 2% with Adrenaline (0.005mg to 0.0125mg) 30 ml | 2400 | Vial |
| 433 | Lignocaine HCL 2% Viscous 100 ml Bottle Oral topical solution | 1100 | Bottle |
| 434 | Lignocaine HCL 4% 30 ml Topical solution Vial/Bottle | 1300 | Vial /Bottle |
| 435 | Lignocaine HCl 50 ml for IV use each ml containing Lignocaine HCl 21.3 mg, Sodium chloride 6.0 mg Vial | 2600 | Vial |
| 436 | Linezolid 600 mg/ 300 ml Bottle | 6300 | Bottle |
| 437 | Liposomal Amphotericin B 50 mg Amp/ Vial | 2300 | Amp/ vial |
| 438 | Lorazepam 4 mg/ 2 ml Amp | 8800 | Amp |
| 439 | Low molecular weight Heparin 20 mg/ 0.2 ml(2000 Anti-xa IU) PFS (Enoxaparin) | 15000 | PFS |
| 440 | Low molecular weight Heparin 40 mg/ 0.4 ml(4000 Anti-xa IU) PFS (Enoxaparin) | 26500 | PFS |

| | | | |
|-----|--|---------------|-----------|
| 441 | Low molecular weight Heparin 60 mg/0.6 ml(6000 Anti-xa IU) PFS (Enoxaparin) | 32000 | PFS |
| 442 | Magnesium sulphate 50% 2 ml Amp | 57000 | Amp |
| 443 | Melphalan 50 mg Vial | 120 | Vial |
| 444 | Mephentermine sulphate 30 mg/ ml 10 ml for IV use Vial | 3000 | Vial |
| 445 | Methylene Blue 10 mg/ ml | 200 | Amp/ vial |
| 446 | Meropenem 500 mg Vial | 6400 | Vial |
| 447 | Meropenem 1gm Vial | 46000 | Vial |
| 448 | Mesna 200 mg/ 2 ml Amp | 5100 | Amp |
| 449 | Methotrexate 15 mg Vial | 2000 | Vial |
| 450 | Methotrexate 50 mg Preservative free for IV, IM, Intrathecal Use Vial | 10000 | Vial |
| 451 | Methotrexate 1gm Preservative free Vial | 1600 | Vial |
| 452 | Methyl prednisolone 500 mg Vial | 600 | Vial |
| 453 | Methyl prednisolone sodium succinate 500 mg Vial | 600 | Vial |
| 454 | Methyl prednisolone sodium succinate 1gm Vial | 2800 | Vial |
| 455 | Methylergometrine 0.2 mg/ ml- 1ml Amp | 2000 | Amp |
| 456 | Metoclopramide 10 mg/ 2ml Amp | 36000 | Amp |
| 457 | Metronidazole 500 mg/ 100ml for IV use in Polythene Bottles | 145000 | Bottle |
| 458 | Midazolam 10 mg/ 10ml Vial | 40000 | Vial |
| 459 | Mitomycin C 40 mg Vial | 200 | Vial |
| 460 | N Acetyl cysteine 200 mg/ ml 5 ml for IV use Amp/ Vial | 6800 | Amp/ vial |
| 461 | Neostigmine methylsulphate 2.5 mg / 5 ml Amp | 12300 | Amp |
| 462 | Nimodipine 10 mg/ 50ml Vial | 1000 | Vial |
| 463 | Nitroglycerin 25 mg/ 5ml Amp | 5700 | Amp |
| 464 | Nitroprusside sodium 50 mg Vial | 360 | Vial |
| 465 | Noradrenaline bitartrate 4 mg/ 2 ml Amp | 78000 | Amp |
| 466 | Octreotide acetate 50 mcg/ ml Amp | 41000 | Amp |
| 467 | Ondansetron 8 mg/ 4ml Amp | 133000 | Amp |
| 468 | Oxaliplatin 50 mg Vial | 600 | Vial |
| 469 | Oxaliplatin 100 mg Vial | 2200 | Vial |
| 470 | Oxytocin 5 IU/ ml 1ml for IM, IV use Amp | 150000 | Amp |
| 471 | Paclitaxel 30 mg Vial | 1300 | Vial |
| 472 | Paclitaxel 100 mg Vial | 2200 | Vial |
| 473 | Paclitaxel 260 mg Vial | 1300 | Vial |
| 474 | Pantoprazole 40 mg Vial | 180000 | Vial |
| 475 | Paracetamol 300 mg/ 2ml (Without Lignocaine) for IM,IV use Amp | 22000 | Amp |
| 476 | Paracetamol 1gm/ 100 ml for IV use Bottle | 127000 | Bottle |
| 477 | Pegylated GCSF 6 mg Vial/ PFS | 1500 | Vial/PFS |
| 478 | Pemetrexed 100 mg Vial | 900 | Vial |
| 479 | Pemetrexed 500 mg Vial | 450 | Vial |

| | | | |
|-----|--|---------------|-----------|
| 480 | Phenobarbitone sodium 200 mg/ ml 1ml Amp | 2400 | Amp |
| 481 | Phenylephrine 10 mg/ ml 1ml Amp | 1900 | Amp |
| 482 | Piperacillin 2 gm + Tazobactam 250 mg Vial | 7200 | Vial |
| 483 | Piperacillin 4 gm + Tazobactam 500 mg Vial | 39000 | Vial |
| 484 | Pneumococcal Vaccine 10 valent 0.5 ml Vial/ PFS | 500 | Vial/PFS |
| 485 | Pneumococcal Vaccine 23 valent 0.5 ml Vial/ PFS | 500 | Amp |
| 486 | Polymyxin sulphate 500000 units | 1000 | Vial |
| 487 | Posaconazole 300mg Vial | 500 | Vial |
| 488 | Potassium chloride 15% 10 ml Amp | 80000 | Amp |
| 489 | Promethazine HCl 50 mg/ 2ml Amp | 4500 | Amp |
| 490 | Propofol 10 mg/ ml 20 ml Vial | 16000 | Vial |
| 491 | Prostaglandin E1 500 mcg/ ml Vial | 100 | Vial |
| 492 | Protamine sulphate 1% 5ml Amp | 2400 | Amp |
| 493 | Pyridine aldoxime methiodide 25 mg/ ml (PAM) 20 ml | 10500 | Amp/Vial |
| 494 | Rabies Human Monoclonal Antibody (rDNA) 100 IU/2.5 ml for local infiltration in the wound and IM use | 100 | Amp |
| 495 | Ranitidine 50 mg/ 2ml Amp | 58000 | Amp |
| 496 | Rituximab 100 mg Vial | 700 | Vial |
| 497 | Rituximab 500 mg Vial | 850 | Vial |
| 498 | Rocuronium 50mg/ 5ml Vial | 1650 | Vial |
| 499 | Scorpion Venom Antiserum | 300 | Amp/vial |
| 500 | Sevoflurane 250 ml Bottle in unbreakable medical quality Glass/ Plastic / Aluminium bottle. Quick fill adapter should be coded at both ends / separate adaptor. If adaptor is not fixed to the bottle the Tenderer should supply in the ratio of 4 Bottles : 1 Adaptor | 600 | Bottle |
| 501 | Sildenafil 0.8 mg Amp/ Vial | 100 | Amp/Vial |
| 502 | Sodium bicarbonate 7.5% 10 ml Amp | 105000 | Amp |
| 503 | Sodium valproate 500 mg for IV use Amp/ Vial | 4100 | Amp/ Vial |
| 504 | Streptokinase 1.5 million IU Vial | 600 | Vial |
| 505 | Succinyl choline chloride 50 mg/ ml 10 ml Vial | 2800 | Vial |
| 506 | Tdap vaccine 0.5ml Vial/ PFS | 1500 | Vial/PFS |
| 507 | Teicoplanin 400 mg Vial | 700 | Vial |
| 508 | Tenecteplase 20mg Vial | 200 | Vial |
| 509 | Terbutaline sulphate 0.5 mg/ ml 1ml Amp | 620 | Amp |
| 510 | Teriparatide (1- 34 Parathyroid Hormone) 250mcg / ml - 3 ml | 300 | Cartridge |
| 511 | Terlipressin 1mg / 10ml | 2000 | Amp |
| 512 | Tetanus Toxoid 0.5ml / Dose - 5ml Vial | 3800 | Vial |
| 513 | Tetanus and Adult Diphtheria Vaccine (Td Vaccine) Vial | 3800 | Vial |
| 514 | Thiopentone sodium 1gm 20 ml Vial | 4800 | Vial |
| 515 | Tigecycline 50 mg | 500 | Vial |
| 516 | Tramadol HCl 100 mg/ 2 ml Amp/ Vial | 108000 | Amp/Vial |

| | | | |
|--|--|-------|----------|
| 517 | Tranexamic acid 500 mg/ 5ml Amp/ Vial | 20000 | Amp/Vial |
| 518 | Trastuzumab 440 mg | 600 | Vial |
| 519 | Triamcinolone acetonide 40 mg/ ml 1ml Vial | 7800 | Vial |
| 520 | Vancomycin 500 mg Vial | 10000 | Vial |
| 521 | Vancomycin 1gm Vial | 19000 | Vial |
| 522 | Varicella Zoster Immunoglobulin 125 IU 5ml Amp/Vial | 500 | Amp/Vial |
| 523 | Vasopressin 20 IU/ ml 1ml Amp/ Vial | 5400 | Amp/Vial |
| 524 | Vecuronium bromide 4 mg Lyophilised Amp/ Vial | 30000 | Amp/Vial |
| 525 | Verapamil 5 mg/ 2 ml 2 ml Amp | 1000 | Amp |
| 526 | Vinblastine 10 mg/ 10 ml Vial | 700 | Vial |
| 527 | Vincristine sulphate 1 mg Vial | 3600 | Vial |
| 528 | Vinorelbine 50 mg Vial | 300 | Vial |
| 529 | Vitamin K ₁ (Phyto menadione) 1mg/ 0.5 ml Amp | 19000 | Amp |
| 530 | Vitamin K ₃ (Menadione) 10 mg/ ml Amp | 19000 | Amp |
| 531 | Voriconazole 200 mg Vial | 2000 | Vial |
| 532 | Water for Injection Sterile 10 ml in plastic ampoule | 65000 | Amp |
| 533 | Water for Injection Sterile 500 ml in glass bottle | 46000 | Bottle |
| 534 | Zoledronic acid 4 mg Vial | 2600 | Vial |
| <p>For Sl. No. 496 & 497 The lowest bidder will be selected by comparing cumulative price of Inj. Rituximab 100 mg and Inj. Rituximab 500 mg. Hence, the bidders are requested to quote for both the strengths. Selections with mixing of strengths in different brands are not permitted.</p> | | | |

IV FLUIDS

Samples for quoted IV fluids should be sent to the Head, Dept. of Pharmacy, JIPMER, Puducherry 605 006, before the last date of tender. All Intravenous fluids must be manufactured using FFS technology.

| | | | |
|-----|--|--------|--------|
| 535 | Compound Sodium lactate (Ringer lactate solution for injection) 500 ml Bottle FFS pack | 175000 | Bottle |
| 536 | Dextrose Injection 5% 500 ml Bottle FFS pack | 84000 | Bottle |
| 537 | Dextrose injection 5%+Normal saline 0.9% 500 ml Bottle FFS pack | 10000 | Bottle |
| 538 | Dextrose Injection 10% 500 ml Bottle FFS pack | 21000 | Bottle |
| 539 | Dextrose Injection 25% 100 ml Bottle FFS pack | 84000 | Bottle |
| 540 | Glycine solution 1.5%, in 3 litres Polythene Bottle for medical use | 1200 | Bottle |
| 541 | Low molecular weight Dextran 40 with Normal saline/ Dextrose 500 ml Bottle FFS pack | 700 | Bottle |
| 542 | Mannitol Injection 20% 350 ml Bottle FFS pack | 28000 | Bottle |
| 543 | Paediatric maintenance solution with 5% dextrose 500 ml Bottle FFS pack | 2800 | Bottle |
| 544 | Peritoneal dialysis fluid in 1 ltr Polythene Bottle | 2100 | Bottle |
| 545 | Sodium chloride injection 0.45% 500 ml Bottle FFS pack | 2800 | Bottle |
| 546 | Sodium chloride injection 0.9% 100 ml Bottle FFS pack | 350000 | Bottle |
| 547 | Sodium chloride injection 0.9% 500 ml Bottle FFS pack | 700000 | Bottle |

| | | | |
|---|--|-------|--------|
| 548 | Sodium chloride injection 0.9% 3 Ltr Bottle FFS Pack | 2800 | Bottle |
| FOLLOWING SHOULD BE IN COLLAPSIBLE/FLEXIBLE BAGS | | | |
| 549 | Compound Sodium lactate (Ringer lactate solution for injection) 500 ml in collapsible /flexible bags | 75000 | Bag |
| 550 | Continuous ambulatory dialysis fluid 1.5%, 2000 ml Bag with following specifications 1. Made of easily bio gradable material like PL146 plastic or polyolene. 2. Connectology should be such as to have minimal peritonitis incidence like integrated asymmetric Y configuration or central switch system regulating fluid flow. 3. Separate medication port on dialysis bag | 45000 | Bag |
| 551 | Continuous ambulatory dialysis fluid 2.5%, 2000 ml Bag with following specifications 1. Made of easily bio gradable material like PL146 plastic or polyolene. 2. Connectology should be such as to have minimal peritonitis incidence like integrated asymmetric Y configuration or central switch system regulating fluid flow. 3. Separate medication port on dialysis bag | 45000 | Bag |
| 552 | Continuous ambulatory dialysis fluid 4.25%, 2000 ml Bag with following specifications 1. Made of easily bio gradable material like PL146 plastic or polyolene. 2. Connectology should be such as to have minimal peritonitis incidence like integrated asymmetric Y configuration or central switch system regulating fluid flow. 3. Separate medication port on dialysis bag | 1400 | Bag |
| 553 | Dextrose 5%- 500 ml | 23800 | Bag |
| 554 | Glycine 1.5% 3 L in collapsible bags | 2800 | Bag |
| 555 | Hydroxy ethyl starch (Tetra starch) MW 130000 - 500 ml Bag | 4200 | Bag |

| | | | |
|---|---|-------|--------|
| 556 | Physiologically balanced crystalloid non calcium solution for intravascular administration containing sodium chloride 5.26 g/L, sodium gluconate 5.02 g/L, sodium acetate trihydrate 3.68 g/L, potassium chloride 0.37g/L, magnesium chloride 0.3g/L. Should have the osmolality and pH status similar to that of Normal Plasma. 294mOsmol/L and pH 7.4(range 6.5-8).Should have the following ionic concentration Sodium -140, Potassium -5,magnesium-3 Acetate-27, Chloride -98,gluconate-23 and no calcium. Should be dispensed in a sterile self collapsible transparent bag of medical grade poly vinyl chloride with a capacity of 500 ml - 1000 ml with two ports. | 13000 | Bag |
| 557 | Sterile perfusion fluid for organ preservation for transplantation (such as Euro Collins or HTK solution) in 1 litre collapsible bag | 80 | Bag |
| 558 | Sodium chloride injection 0.9% 100 ml in collapsible/flexible bags | 35000 | Bag |
| 559 | Sodium chloride injection 0.9% 500 ml in collapsible/flexible bags | 65000 | Bag |
| 560 | Sodium chloride injection 0.9% 3 Ltr infusion bag | 3500 | Bag |
| 561 | Total Parenteral Nutrition solution in 3 chamber single bag having PVC free, DEHP free container with needle free access and latex free injection port with strong hanger. Volume should be 1400- 1500ml. Calories provided should be 800-1000 kilocalories, Glucose 90- 110gm per 1500ml, protein content should be 30-50gm per 1500ml, lipid emulsion should be30-50gms per 1500ml with a mixture of LCT, MCT, olive oil/ fish oil /Soya oil. Should also contain micro nutrients like trace elements, zinc and taurine. Should have an osmolality permitting to be infused through peripheral vein (< 900 mosm/L) | 3000 | Bag |
| 562 | Total Parenteral Nutrition solution in 3 chamber single bag having PVC free, DEHP free container with needle free access and latex free injection port with strong hanger. Volume should be 1400 - 1500ml. Calories provided should be 1500-1600 kilocalories, Glucose 170- 190gm per 1500ml, protein content should be 60-75gm per 1500 ml, lipid emulsion should be50-60gms per 1500ml ,with a mixture of LCT, MCT, olive oil/ fish oil /Soya oil. Should also contain micro nutrients like trace elements, zinc and taurine. Should have an osmolality permitting to be infused through central vein (> 900 mosm/L) | 3000 | Bag |
| 563 | UW Solution in 1 Ltr Bag (University of Wisconsin solution) | 140 | Bag |
| FOLLOWING SHOULD BE IN GLASS BOTTLES | | | |
| 564 | Sodium chloride injection 0.9% 100 ml Glass bottle | 21000 | Bottle |
| 565 | Sodium chloride injection 3% 100 ml Glass bottle | 24000 | Bottle |

| <u>POWDERS</u> | | | |
|---|---|-------|--------|
| 566 | Activated Charcoal IP 250 gm | 3500 | Sachet |
| 567 | Arginine Sachet | 21000 | Sachet |
| 568 | Azulene 2.01 mg +L-glutamic acid 663.3 mg | 14000 | Sachet |
| 569 | Calcium polystyrene Sulphonate 15 gm Sachet (K exchange resin) | 12600 | Sachet |
| 570 | Dextrose Monohydrate IP oral 75 gm packet | 6300 | Packet |
| 571 | Fosfomycin Powder 3 gm Sachet | 280 | Sachet |
| 572 | L-Ornithine + L-Aspartate Sachet 5 gm | 7000 | Sachet |
| 573 | Mesalazine Sachet 1 gm | 30000 | Sachet |
| 574 | Oral Rehydration powder latest WHO citrate formula 20.5 gm packet (each pack containing: Sodium Chloride I.P. 2.6 gm, Potassium Chloride I.P. 1.5 gm, Trisodium Citrate dihydrate I.P. 2.9 gm, Glucose (Anhydrous) I.P.13.5 gm) | 60000 | Packet |
| 575 | Polyethylene glycol electrolyte powder for oral use for bowel preparation containing 118 g, in sachet with flavour | 30000 | Sachet |
| 576 | Polyethylene glycol 17.1 gm+ Dimethicone | 30000 | Sachet |
| 577 | Saccharomyces boulardii Sachet 250 mg | 2800 | Sachet |
| 578 | Vitamin D-3 cholecalciferol granules 60000 units per sachet | 1400 | Sachet |
| <u>SYRUPS, SUSPENSIONS AND DROPS</u> | | | |
| 579 | Ampicillin + Cloxacillin 125 mg/5 ml Suspension 60 ml Bottle | 1260 | Bottle |
| 580 | Antacid liquid 5 ml containing magnesium hydroxide 250 mg, dried aluminium hydroxide 250 mg with suitable flavour 200 ml Bottle | 9800 | Bottle |
| 581 | Caffeine citrate suspension 60 mg Bottle | 840 | Bottle |
| 582 | Cotrimoxazole suspension 5 ml containing Trimethoprim 40 mg +Sulphamethoxazole 200 mg- 50 ml Bottle | 700 | Bottle |
| 583 | Cyclosporin 100 mg/ml - 50 ml or more | 100 | Bottle |
| 584 | Digoxin 50 mcg syrup/suspension 30 ml Bottle | 420 | Bottle |
| 585 | Ibuprofen suspension 100 mg/5 ml 60 ml Bottle | 420 | Bottle |
| 586 | Iron drops 15 ml Bottle | 140 | Bottle |
| 587 | Oseltamivir 12 mg/ml in the range of 30 ml-100 ml Bottle | 400 | Bottle |
| 588 | Lactitol 66.67% W/V Syrup 200 ml | 280 | Bottle |
| 589 | Lactulose 3.325 g/5 ml syrup 100 ml Bottle | 15000 | Bottle |
| 590 | Midazolam Syrup 2mg/ml | 420 | Bottle |
| 591 | Nicotine Gum | 70000 | No. |
| 592 | Paracetamol syrup 125 mg/5 ml 60 ml Bottle | 56000 | Bottle |
| 593 | Phenobarbitone syrup 20 mg/5 ml 60 ml Bottle | 140 | Bottle |
| 594 | Phenytoin suspension 25 mg/ml 100 ml Bottle | 140 | Bottle |
| 595 | Polyethylene glycol 3350 Syrup | 140 | Bottle |
| 596 | Posaconazole 40 mg/ml | 1414 | Bottle |
| 597 | Promethazine HCl Elixir/syrup 5 mg/5 ml 60 ml Bottle | 70000 | Bottle |
| 598 | Sucralfate syrup 1 gm/5 ml in the range of 100 ml-200 ml Bottle | 280 | Bottle |
| 599 | Triclofos Sodium syrup 500 mg/5 ml 30 ml Bottle | 140 | Bottle |

| | | | |
|-----|---|------|--------|
| 600 | Ursodeoxycholic acid suspension 125 mg/5 ml 100 ml Bottle | 140 | Bottle |
| 601 | Valproic Acid 40 mg/ml Syrup/Suspension 100 ml Bottle | 140 | Bottle |
| 602 | Vitamin A solution/Drops 100 ml Bottle | 140 | Bottle |
| 603 | Zinc syrup 20mg / 5ml in the range of 50ml-100 ml Bottle | 6000 | Bottle |

NARCOTIC ITEMS

| | | | |
|-----|---|--------------|--------|
| 604 | Methadone 5 mg | 48000 | Tablet |
| 605 | Morphine sulphate 10 mg | 72000 | Tablet |
| 606 | Morphine sulphate 20 mg | 30000 | Tablet |
| 607 | Morphine sulphate 30 mg | 20000 | Tablet |
| 608 | Morphine sulphate 10 mg CR/ SR | 48000 | Tablet |
| 609 | Morphine sulphate 30 mg CR/SR | 72000 | Tablet |
| 610 | Fentanyl patch 2.5 mg (Duration 72 hrs, 25 mcg/ hr) | 360 | Patch |
| 611 | Fentanyl patch 5 mg (Duration 72 hrs, 50 mcg/ hr) | 360 | Patch |
| 612 | Fentanyl citrate 0.1 mg/ 2 ml | 96000 | Amp |
| 613 | Morphine sulphate IP -10 mg | 96000 | Amp |
| 614 | Morphine sulphate IP -15 mg | 30000 | Amp |
| 615 | Pethidine HCl IP 50 mg/ ml -1 ml | 6000 | Amp |
| 616 | Pethidine HCl IP 50 mg/ ml -2 ml | 4000 | Amp |
| 617 | Sufentanyl citrate 50 mg/ ml - 1 ml | 2400 | Amp |

Samples for quoted Disinfecting fluids should be sent to the **Head, Dept. of Pharmacy, JIPMER, Puducherry- 605006** before the last date of the tender. Quotations with lower specifications than mentioned below will not be considered.

| | | | |
|-----|--|-------|--------|
| 618 | Antiseptic liquid, Dichloroxylenol 2% & Terpineol 1.75% - 2% RWC 4, 25 litre Pack | 60000 | Ltr |
| 619 | Benzalkonium chloride 2 to 2.5% w/w Based Disinfectant with deodorant | 45000 | Ltr |
| 620 | Cetrimide IP 15% w/v Isopropyl alcohol 6-8% v/v and Chlorhexidine gluconate solution 7.5% v/v 1Ltr. Pack | 15000 | Bottle |
| 621 | Hydrogen peroxide 6% v/v (20vols) IP 100ml Bottle | 15000 | Bottle |
| 622 | Liquid paraffin IP 5 Ltr pack | 8000 | Ltr |
| 623 | Lysol (50% Cresol with Soap solution) IP 10 Ltrs pack | 45000 | Ltr |
| 624 | Obstetric Cream containing Dichloroxylenol 1 % & Terpineol 1% - 2% in the range of 400 to 500gm Jar | 250 | Jar |
| 625 | Povidone iodine solution 5 % 500 ml Bottle | 12000 | Bottle |
| 626 | Solvent Ether IP 500ml Bottle | 2500 | Bottle |
| 627 | Spirit Denatured | 12000 | Ltr |
| 628 | Spirit Rectified | 3500 | Ltr |
| 629 | Surgical Spirit IP 5 Ltrs | 12000 | Ltr |
| 630 | Talc Purified IP in the range of 400 gm to 500 gm Packet | 500 | Packet |
| 631 | Tincture Benzoin Compound IP 500 ml Bottle | 1600 | Bottle |
| 632 | White phenyl 20 litre pack (Deodorant) | 90000 | Ltr |

SURGICAL DRESSING ITEMS

Samples for quoted surgical dressing should be sent to the **Head, Dept. of Pharmacy, JIPMER, Puducherry 605006** before the last date of the tender . Quotations with lower specifications than mentioned

| | | | |
|-------------------------------|--|--------|------------------|
| below will not be considered. | | | |
| 633 | Bandage "T" shaped CALICO IND:MED:TC:0180(B) | 2000 | Packet |
| 634 | Bandage cotton Bandage cloth bleached in size of 10cm x 4mtrs in roll, Min. wt. of each roll should be 20.8gm, as per Schedule F(II) of Drugs and Cosmetics Act 1940 | 500000 | Roll |
| 635 | Bandage crepe 10cm x 4 mtrs IS:4605 1981 with latest amendment/BP. | 9000 | Roll |
| 636 | Bandage elastic Adhesive 10 cm x 4/6 mtr IS:4717:1980/BP | 36000 | Roll |
| 637 | Bandage triangular uncompressed IND:MED:TC:0579 | 1200 | Packet |
| 638 | Handloom cotton bandage cloth bleached 1 metre wide and piece length 20 mtrs. min. wt. 1040gm packet as per schedule F(II) of Drug and cosmetics Act 1940 | 18000 | 20 mtr Packet |
| 639 | Handloom cotton gauze absorbent 50cm x 20 mtrs with min. wt. of 250 gm packet as per schedule F(II) of Drug and cosmetics Act 1940 | 110000 | 20 mtr Packet |
| 640 | Handloom cotton gauze absorbent 100 cm x 20 mtrs with min. wt. of 500 gm packet as per schedule F(II) of Drug and cosmetics Act 1940 | 35000 | 20 mtr Packet |
| 641 | Lint. PLAIN Packet Minimum weight of 400 gm IP/IS:757:1961 with latest amendment | 26000 | Packet |
| 642 | Plaster adhesive zinc oxide 7.5 cmx5 mtrs | 12000 | Spool |
| 643 | Plaster of paris bandage 7.5 cm x 2.7 meters | 7000 | Roll |
| 644 | Plaster of paris Bandage 10 cm x 2.7 meters | 12000 | Roll |
| 645 | Plaster of paris Bandage 15 cm x 2.7 meters | 40000 | Roll |
| 646 | Plaster of Paris Powder IP PACKED in POLYTHENE BAGS IN AIR-TIGHT Tin. 5/10kg | 1000 | Kg |
| 647 | Starched Bandage ordinary gauze loose woven for Plaster of Paris bandage 15cm x 5meters YARN IS:4738:1980 with latest amendment | 8000 | Roll |
| 648 | Wool cotton absorbent IP in packet of 500gm Net wt | 120000 | Roll |
| <u>MISCELLANEOUS</u> | | | |
| 649 | Empty A-type Medical Oxygen Cylinder ISI marked (Without Cap) Medical Oxygen Cylinder with valve 4OCFT ISI marked IS No 7285- 1988 and amended up-to-date /ISO 9809 | 70 | cylinder |
| 650 | Empty B-type Medical Oxygen Cylinder ISI marked (Without Cap) Medical Oxygen Cylinder with valve 4OCFT ISI marked IS No 7285- 1988 and amended up-to-date /ISO 9809 | 700 | cylinder |
| 651 | Acridflavin 1:1000 N 500 ml | 2000 | Bottle |
| 652 | Antiseptic Mouthwash (Listerine Formula) 100 ml | 24000 | Bottle |
| 653 | Boric Alcohol Ear Drops 4-5% 10ml | 3000 | Vials |
| 654 | Boroglycerine 20-25% 10 ml | 1200 | Vials |

| | | | |
|-----|--|--------|--------|
| 655 | Calamine Lotion IP 100 ml Composition Calamine BP 150 g Zinc Oxide BP 50 g Bentonite BP 30 g Sodium Citrate BP 5 g Liquefied Phenol BP 5 mL Glycerine BP 50 mL Freshly boiled and cooled purified water to 1000 mL | 30000 | Bottle |
| 656 | Cetrimide Lotion 1% 120 ml | 12000 | Bottle |
| 657 | Candy's Lotion 1% 500 ml | 60 | Bottle |
| 658 | Cough Syrup with Dextromethorphan | 24000 | Bottle |
| 659 | Dressing Saline 0.9% 1000 ml | 12000 | Bottle |
| 660 | Eusol 1-2% 1000 ml | 10000 | Bottle |
| 661 | Gentian Violet Paint 1 % 10 ml | 2000 | vial |
| 662 | Glucoglycerine Nasal Drops 25% 10 ml | 600 | vial |
| 663 | Glycerine Acriflavin 1:100 250 gm | 200 | Bottle |
| 664 | Glycerine Ichthamol Paint 10 % 250 gm | 840 | Bottle |
| 665 | Glycerine Magnesium Sulphate 15-20% 250 gm | 15000 | Bottle |
| 666 | Ichthammol 10% salicylic acid 3-5% ointment 25 gm | 24000 | tube |
| 667 | Joulie's Solution (Oral) 1000 ml Composition Dibasic Sodium Phosphate- 5.4 gm, Phosphoric Acid-3.4 ml and Water qs to 100 ml | 50 | Bottle |
| 668 | Linctus Codeine 0.125 % 100 ml | 24000 | Bottle |
| 669 | Lugol's Iodine IP 200 ml | 100 | Bottle |
| 670 | Methylene Blue 1% Topical solution 200 ml | 100 | Bottle |
| 671 | Mixture Cough Expectorant 60-100 ml containing Bromhexine 4 mg/5 ml | 24000 | Bottle |
| 672 | Oral Glycerol 10 % 500 ml | 3000 | Bottle |
| 673 | Potassium Chloride Mixture 1 200 ml | 120000 | Bottle |
| 674 | Propranolol 1 % Cream 5 gm | 200 | tube |
| 675 | Salicylic Acid Ointment 3.3% 25 gm | 3000 | tube |
| 676 | Salicylic Acid Ointment 6% 25 gm | 6000 | tube |
| 677 | Salicylic Acid Ointment 10% 25 gm | 2500 | tube |
| 678 | Salicylic Acid Ointment 20% 25 gm | 1200 | tube |
| 679 | Salicylic Acid Ointment 40% 25 gm | 600 | tube |
| 680 | Saturated solution Potassium Iodide (oral) 100 ml | 10 | Bottle |
| 681 | Shohl's Solution (Oral) 500 ml Composition Citric Acid- 12.8 gm Sodium Citrate-9.8 gm water qs to 100 ml | 10 | Bottle |
| 682 | Sodium Bicarbonate 3-5% Glycerine 50% Ear Drops 10 ml | 2400 | vial |
| 683 | Sodium Thiosulphate (Hypo) Solution 20 % 100 ml | 300 | Bottle |
| 684 | Sulphur Ointment 10% 25 gm | 120 | tube |

| | | | |
|------------------|---|--------|------|
| 685 | Whitfield ointment 25 gm Composition Salicylic acid-3 gm Benzoic Acid-6 gm Yellow Soft Paraffin qs to 100 gm | 1200 | tube |
| 686 | Yellow Soft Paraffin 25 gm | 50000 | tube |
| 687 | Zinc Oxide Ointment 15 % 25 gm | 40000 | tube |
| CHEMICALS | | | |
| 688 | Acid Acetic Glacial IP in the range of 400- 500 ml | 24000 | ml |
| 689 | Acid Benzoic IP 500 gm | 14000 | gm |
| 690 | Acid Boric IP in the range of 400- 500 gm | 112000 | gm |
| 691 | Acid Salicylic IP in the range of 400- 500gm | 14000 | gm |
| 692 | Acriflavin IP 20gm | 400 | gm |
| 693 | Ammonium chloride IP 400gm | 210000 | gm |
| 694 | Borax IP 400gm | 14000 | gm |
| 695 | Cetrimide IP 1kg | 14 | kg |
| 696 | Ephedrine HCL IP 1Kg | 4000 | gm |
| 697 | Gentian violet crystals IP 20gm | 600 | gm |
| 698 | Glycerine IP 1Kg | 1750 | Kg |
| 699 | Ichthammol IP 400gm | 28000 | gm |
| 700 | Iodine crystal IP 50gm in airtight container | 350 | gm |
| 701 | Linimentum Turpentine IP 1 Ltr | 3600 | Lit |
| 702 | Liquid extract of Liquorice IP in the range of 400-500ml | 420000 | ml |
| 703 | Magnesium sulphate IP 400-500 gm | 100000 | gm |
| 704 | Menthol Crystals IP in the range of 400gm- 1Kg in air tight container | 5600 | gm |
| 705 | Methyl salicylate IP in the range of 400-500gm | 5600 | gm |
| 706 | Methylene blue IP 20gm | 300 | gm |
| 707 | Oil of eucalyptus IP in the range of 400-500ml | 5600 | ml |
| 708 | Potassium Chloride IP 400-500 gm | 280000 | gm |
| 709 | Potassium Iodide IP in the range of 400-500gm | 3500 | gm |
| 710 | Sodium Bicarbonate Powder IP 400-500 gm | 560000 | gm |
| 711 | Sodium Chloride IP in the range of 400-500 gm | 84000 | gm |
| 712 | Sodium Thiosulphate IP 400-500 gm | 14000 | gm |
| 713 | Sy Codeine phosphate IP in the range 200- 400gm | 280000 | gm |
| 714 | Sy Tolu IP 600gm | 280000 | gm |
| 715 | Thymol IP 100gm in air tight container | 5600 | gm |
| 716 | Tincture Opium IP 400ml | 10000 | ml |
| 717 | Yellow soft paraffin IP 1Kg | 3500 | Kg |
| 718 | Zinc Oxide IP 1 Kg | 100 | Kg |

II. TERMS & CONDITIONS OF E-TENDER

1. Estimated tender value: - **Rs.30,00,00,000/-** (approx.) (Rupees Thirty Crores only) for 12 months.
2. Period of contract: The contract shall initially be for a period of 12 months (1st December 2020 to 30th November 2021) and may be extended further for a period up to three months on the same terms and conditions. The rates approved shall remain unchanged during the period of contract.
3. Earnest Money Deposit: Rs.50,000/- (Rupees Fifty thousand only) and a non-refundable Tender Processing fee: Rs.590/- (Inclusive of 18% GST) to be deposited, through SBI collect only. No other form of payment such as demand draft or cheque is not acceptable.
4. Micro and Small Enterprises and Small Scale Industries are exempted for EMD as per JIPMER purchase guidelines. However, there is no exemption for payment of Tender processing fee.
5. Last date of submission: Last Date for submission of the e-tender is on or before **04.11.2020 at 12.00 Noon.**
6. Date of opening the e-tender: The e-tender will be opened on **05.11.2020 at 02.30 PM.**
The e-tender shall be opened in presence of the bidders who choose to be present during opening of bids.
7. Pre-Bid Meeting: A pre bid meeting shall be held on **16.10.2020 at 02.30 PM** in the Purchase Section, Administrative Block, JIPMER, Puducherry.

III.A. Eligibility conditions of bidders:

1. Original Manufacturers and Original Direct Importers (product under trade mark/ solely marketed/ loan license should bear name of tender participant on the label, (i.e., name of the tender participant should be on the supplied product of drugs) only should quote their rates. Orders will be placed with the selected tender parties and payment will be made to them directly.
2. **Companies having annual turnover of Rupees 50 crores and above in 2018-19 or 2017-18 (any one year as per the audited balance sheet) are only eligible to participate.** Necessary certification in proof of this in the form of a certificate issued by the auditor in original should be submitted.
3. Original Manufacturers or Original direct importer's principal firm should have **at least 3 years market standing** as a manufacturer/direct importer respectively for each drug quoted in the tender. Copy of the Manufacturing License/Import License renewed under Drugs and Cosmetics Act 1940 with approved list of drugs under the license should be furnished for a period of three years up to 2020.
4. The Tenderer should provide a notarized affidavit that they have not been blacklisted due to quality failure or any other issue for the quoted product /firm by any State Government / Central Government / its Drug procurement agencies during the last 3 years.

5. The Tenderer has to submit Non Conviction Certificate from State Drugs Controller stating that no case is pending against the organization under the “Drugs and Cosmetics Act and Rules” as well as under the “Drugs Price Control Order” issued from time to time.

6. In compliance with order (Public Procurement No.1) No. 6/18/2019-PPD dated 23rd July 2020 issued by the Public Procurement Division, Dept of Expenditure, Min Of Finance under Rule 144(xi) of GFR 2017 any bidder 'from a country which shares a land border with India will be eligible to bid in this tender only if the bidder is registered with the Competent Authority.
 - a. "Bidder" (including the term 'tenderer', 'consultant' or 'service provider' in certain contexts) means any person or firm or company, including any member of a consortium or joint venture (that is an association of several persons, or firms or companies), every artificial juridical person not falling in any of the descriptions of bidders stated hereinbefore, including any agency branch or office controlled by such person, participating in a procurement process
 - b. "Bidder from a country which shares a land border with India" for the purpose of this Order means: -
 - i. An entity incorporated, established or registered in such a country; or
 - ii. A subsidiary of an entity incorporated, established or registered in such a country; or
 - iii. An entity substantially controlled through entities incorporated, established or registered in such a country; or
 - iv. An entity whose beneficial owner is situated in such a country; or
 - v. An Indian (or other) agent of such an entity; or
 - vi. A natural person who is a citizen of such a country; or
 - vii. A consortium or joint venture where any member of the consortium or joint venture falls under any of the above.
 - c. The beneficial owner for the purpose of (iv) above will be as under:
 - i. In case of a company or Limited Liability Partnership , the beneficial owner is the natural person(s), who, whether acting alone or together, or through one or more juridical person, has a controlling ownership interest or who exercises control through other means.
Explanation—
 1. “Controlling ownership interest" means ownership of or entitlement to more than twenty-five per cent, of shares or capital or profits of the company.
 2. "Control" shall include the right to appoint majority of the directors or to control the management or policy decisions including by virtue of their shareholding or management rights or shareholders agreements or voting agreements.
 - ii. In case of a partnership firm, the beneficial owner is the natural person(s) who, whether acting alone or together, or through one or more juridical person, has ownership of entitlement to more than fifteen percent of capital or profits of the partnership.
 - iii. In case of an unincorporated association or body of individuals, the beneficial owner is the natural person(s) , who, whether acting alone or together, or through one or more juridical person, has ownership of

entitlement to more than fifteen percent of the property or capital or profits of such association or body of individuals.

- iv. Where no natural person is identified under (i) or (ii) or (iii) above, the beneficial owner is the relevant natural person who holds the position of senior managing official.
 - v. In case of a trust, the identification of the beneficial owner(s) shall include the identification of the author of the trust, the trustee, the beneficiaries with 15% or more interest in the trust and any other natural person exercising ultimate effective control over the trust through a chain of control or ownership.
 - d. An Agent is a person employed to do any act for another, or to represent another in dealings with third person.
 - e. In case of turnkey contracts, the successful bidder shall not be allowed to sub-contract works to any contractor from a country which shares a land border with India unless such contractor is registered with the Competent Authority.
 - f. Bidders must include a paragraph as a certificate of compliance with the abovementioned provisions in the tender form given in the annexure.
7. Tender should not be submitted for the product(s) for which the firm / company has been blacklisted by any State Government (like TNMSC)/ Central Government / its Drug procurement agencies due to any issue in last 3 years.
 8. The Companies/Firms which have been blacklisted by any State Government/Central Government / its Drug procurement agencies due to quality failure of the drugs supplied should not participate in the tender.
 9. The companies blacklisted by JIPMER for more than two times are not eligible to participate in the tender and such companies should refrain themselves from participating in the tender.
 10. The companies having any kind of DUES with JIPMER are NOT ELIGIBLE to participate in the tender.

III B. Eligibility Criteria for Bidders of Renal Transplant Drugs (Tacrolimus and mycophenolate)

1. The company should have a market standing for Tacrolimus/Mycophenolate for a minimum of 10 years.
or
Should have experience in handling the active pharmaceutical ingredient (Tacrolimus/Mycophenolate) for a minimum period of 10 years and market standing for the formulation of Tacrolimus/Mycophenolate for a minimum of 3 years.
Copy of the Manufacturing License/Import License renewed under Drugs and Cosmetics Act 1940 should be furnished for a period of ten years up to 2020.
2. The manufacturer should have to submit utilization certificate for use of their brand of Tacrolimus/Mycophenolate for a period of more than one year from Head of the department of Nephrology of a government hospital performing more than 50 kidney transplant surgeries per year.

3. All bidders are requested to quote their rate for all strengths of Tacrolimus/Mycophenolate. Bidders not quoting rates for all the strengths will not be considered.
4. The lowest bidder will be selected by comparing the weighted cumulative rate. The weighted cumulative rate will be calculated as follows.
 - i) Weighted cumulative rate for Tacrolimus = $0.02 \times (\text{rate of } 0.25 \text{ mg}) + 0.2 \times (\text{rate of } 0.5 \text{ mg}) + 0.28 \times (\text{rate of } 1 \text{ mg}) + 0.5 \times (\text{rate of } 2 \text{ mg})$
 - ii) Weighted cumulative rate for Mycophenolate = $0.15 \times (\text{rate of } 250 \text{ mg}) + 0.85 \times (\text{rate of } 500 \text{ mg})$

III C. Criteria for selecting Biologicals (Rituximab)

1. Bidders are requested to quote for both the strength (100 mg & 500 mg) of Rituximab.
2. Selection will be based on the weighted cumulative rate calculated as mentioned below:

$$\text{Weighted cumulative rate for Rituximab} = 0.45 \times (\text{rate of rituximab } 100\text{mg}) + 0.55 \times (\text{rate of rituximab } 500\text{mg})$$

3. Firms not quoting for both the strengths will not be considered.

IV. INSTRUCTIONS FOR THE BIDDER

1. E-Tender form shall be completed in all respect. Incomplete or e-tenders without EMD (unless eligible for exemption and proof of the same is submitted) shall be treated as invalid.
2. Bidders must ensure that all the documents are properly filled.
3. Director, JIPMER reserves the right to accept or reject (fully or partially) any tender or all tender without assigning any reason.
4. Conditional tenders are liable to be rejected.
5. The EMD of unsuccessful bidders shall be refunded within one month after the award of contract to the successful bidder or in the case of successful bidder, at the end of the contract period after deducting dues from the firm if any.
6. **The successful bidder shall have to deposit an amount 5% of the annual approximate cost as Performance Security Deposit (PSD) within two weeks after award of contract, through SBI collect only. No other mode of payment is acceptable.**
7. Bids received and found valid will be evaluated by JIPMER to ascertain the completeness / correctness of the documents. The bidder should take care to submit all the information sought by JIPMER in prescribed formats.

8. Incomplete bids, bids in paper format, conditional bids, telephonic bids or tenders submitted after the due date and time will not be considered and will be summarily rejected. No grounds whatsoever for late submission shall be entertained such as, but not restricted to, postal, train or flight delays, strikes or agitations of any nature etc. Vendors are, therefore, advised to submit their bids well on time.
9. **Bids of eligible bidders alone will be evaluated on the basis of net rate (basic rate + GST as quoted in the financial bid) and the lowest bid (L1) will be selected except in the case of Tacrolimus/Mycophenolate an Rituximab for which a separate methodology as stated in clause III(B) and III(C) above. Purchase preference as per Government of India orders will be implemented.**

V. SUBMISSION OF TENDERS

1. The bidders must ensure that they submit the **on-line bids only** within the scheduled closing date & time. No physical documents need to be submitted.
2. **Late Tender:**
There is NO PROVISION of uploading late tender beyond stipulated date & time in the e- tendering system.
3. **Alteration and Withdrawal of Tender**
The bidder, after submitting its bid, is permitted to alter/modify its bid, within the deadline for submission of bids. Alterations/modifications to bids received after the prescribed deadline will not be considered.
4. No bid should be withdrawn after the deadline for submission of bid and before expiry of the bid validity period. If a bidder withdraws the bid during this period, it will result in forfeiture of the EMD furnished by the bidder in its bid.

VI. PREPARATION OF e-TENDERS

1. Documents comprising the e-Tender

This is a Two-Bid Tender system, consisting of the **Techno-Commercial Bid and Price Bid** that are to be uploaded in the prescribed formats in the e-tendering portal.

2. The tender(s) shall only be submitted online as mentioned below:

A. Techno-Commercial Bid shall comprise

- i) In the "Fee" Cover
 - a. Scanned copy in pdf format of Tender processing fee payment receipt must be uploaded. Tender processing fee is not exempt for any bidder.
 - b. Scanned copy in pdf format of EMD receipt or, if EMD exemption is claimed, copy of valid registration details proving that the bidder is a Micro or Small enterprise or is registered as a Small Scale Industry

with MSME, as the case may be should be uploaded.

- c. Bidders who had paid tender fee and EMD in full for the tender Pur.8(1)/2020-21/Tender I dt 10.06.2020 which was cancelled need not pay again, provided they have not asked for refund of their EMD. But the bidder should mention in the tender form that they would like to adjust the tender fee and EMD that they had paid for the aforesaid cancelled tender, with the requirements of payment of Tender Processing Fee and EMD of this tender and must upload the same tender fee receipt and EMD payment receipt that they had uploaded in the aforesaid cancelled tender, once again during bid submission for this tender failing which their bid will be rejected.
 - d. New bidders, who had not participated or participated but not paid the requisite Tender Processing Fee or EMD in the above mentioned cancelled tender must pay Tender Processing Fee and Earnest Money Deposit in full to be eligible to participate in this tender.
- ii) In the cover named “**Prequal/Technical**” the scanned copy in pdf format of the following documents are to be uploaded:
- a. **Tender Form** as in Annexure 1 and **Declaration by bidder** as in Annexure 2 must be downloaded, filled in the format prescribed in the firm’s letterhead , signed in full and stamped at the appropriate places by the authorized signatory, **Authorization letter** for signing tender documents if other than the Owner, Partner, Managing Director and **Tender Signing Authority** issued by Competent Authority in favour of the person who is digitally signing/ uploading the tender(s) must be scanned and uploaded as a single pdf file.
 - b. **Non- Blacklisted certificate** – Notarized affidavit (as in Annexure 3), **Non- Conviction Certificate** – from State Drug Controller, and **GMP Certificate / Schedule M compliance** from CDSCO must be scanned and uploaded as a single pdf file.
 - c. Documentary evidence for the constitution of company Like **Article of Association, Copy of GST** registration certificate, **Copy of PAN Card**, Copy of the **Manufacturing License/Import License** renewed under Drugs and Cosmetics Act 1940 with approved list of drugs under the license for a period of three years up to 2020 (as a proof for market standing for three years) and Copy of **certificate empanelment** by the competent authority under GFR 144(xi) wherever applicable must be scanned and uploaded as a single pdf file. (Bidder must go through GFR 144 (xi) in this regard and satisfy himself whether the rule is applicable to him or not)
 - d. Copies of **Supply orders/Completion certificate** in support of Eligibility condition 1 and 2 must be scanned and uploaded as a single pdf file.

- e. **Copies of abridged Auditor's report of last 03 years** (Income tax return acknowledgement, Assets and Liabilities, Balance sheet and Profit & Loss Account), and **Annual turnover statement** of Rs.50 crores for any one year i.e. 2018-19 or 2017-18 certified by Auditor/Chartered Accountant must be scanned and uploaded as a single pdf file.
- f. **Documents for bidders of renal transplant drugs** - Copy of the Manufacturing License/Import License renewed under Drugs and Cosmetics Act 1940 for a period of ten years up to 2020, and **Utilization certificate** for use of their brand of **Tacrolimus/Mycophenolate** for a period of more than one year from Head of the department of Nephrology of a government hospital performing more than 50 kidney transplant surgeries per year must be scanned and uploaded as a single pdf file..
- g. **Checklist** in the prescribed format duly filled and signed, Bidders who are claiming purchase preference under the Public Procurement (Preference to Make in India), order 2017 of MoC and I (DIPP), Govt. Of India are to upload the **self-certification** in the format given in **Appendix A and any other document** the bidder wants to submit must be scanned and uploaded as a single pdf file.

Note:

- i) Bidders must ensure that the documents uploaded in pdf format are legible. Illegible documents will be treated as documents not submitted.
- ii) Bidder must note that the total size of all documents in any one cover, i.e. "Fee cover" and "Prequal/Technical" Cover cannot exceed more than 50 MB. Bidder must accordingly scan, and upload only relevant documents scanned at appropriate resolution such as 200dpi, black and white.

B. Price Bid:

Prices are to be quoted in the prescribed Price Bid format provided in the e-tender portal using the BOQ template only. The price should be quoted for the **accounting unit** indicated in the e-tender document.

Note:

- i) The bidder must be diligent while filling up the Techno-Commercial Bid and Price Bid provided in prescribed formats and must not tamper with the contents of the sheets.
- ii) It is the responsibility of bidder to go through the Tender document to ensure furnishing all required documents in addition to above, if any.
- iii) ITE- Item-wise Eligibility Sheet should be downloaded, the items that the bidder wishes to quote must be selected as "Eligible", and this "ITE file"

must also be uploaded for the price bid to be considered by the system. The selected items will be displayed once uploaded and the bidder can verify that all items he wishes to quote for, are present in the list.

3. A person signing (manually or digitally) the tender form or any documents forming part of the contract on behalf of another shall be deemed to warrant that he has authority to do so and bind such other persons to the contract on whose behalf he is signing and if, on enquiry, it appears that the persons so signing had no authority to do so, the purchaser may, without prejudice to other civil and criminal remedies, cancel the contract and hold the signatory liable for all cost and damages.

4. **Digital Signing of Tender**

The tenderers shall submit their tenders as per the instructions contained as above. Tenders shall be uploaded with all relevant tender documents in the prescribed format. The relevant tender documents should be uploaded by an authorized person having Class 3 digital signature certificate.

5. A bid, which does not fulfil any of the above requirements and/ or give evasive information/reply against any such requirement, shall be liable to be rejected.
6. Tender sent by fax/telex/cable shall be summarily rejected.

7. **Tender currencies.**

The tender shall be quoted only in INR (Indian Rupees).

8. **Additional information and instruction on GST:**

If the Tenderer desires to ask for GST, the same must be specifically indicated in the financial bid. Any other taxes or duties to be paid extra must be included by the tenderer in the unit cost. In the absence of any such stipulation the price will be taken inclusive of such taxes and no claim for the same will be entertained later. The rate of GST quoted in the tender shall be taken for price comparison. However, the rate of GST quoted in the tender or the actual rate of GST applicable, whichever is lower shall be payable by the purchaser. The supplier can charge a higher GST than quoted in the tender only if the rate of GST was revised by the government after the tender closing date. **Tenderer is advised to be particularly careful in filling the GST rate in the financial bid as no upward revision of GST shall be allowed unless the rate is revised by the government after bid submission date.**

VII. **Earnest Money Deposit (EMD)**

1. Pursuant to Tender terms and conditions clause 3 and 4 the tenderer shall furnish along with its tender, earnest money for amount as shown in the List of Requirements. The earnest money is required to protect the purchaser against the risk of the tenderer's unwarranted conduct as amplified under sub-clause, 6 below.

2. The tenderers who are currently registered and, also, will continue to remain registered during the tender validity period as Micro and Small Enterprises (MSEs) as defined in MSE Procurement Policy issued by Department of Micro, Small and Medium Enterprises (MSME) or with National Small Industries Corporation, shall be eligible for exemption from EMD. In case the tenderer falls in this category, it should furnish copy of its valid registration details (with MSME or NSIC, as the case maybe).
3. The earnest money shall be denominated in Indian Rupees only and paid through SBI collect only.
4. The earnest money shall be valid for a period of forty-five (45) days beyond the validity period of the tender.
5. Unsuccessful tenderers' earnest money will be returned to them without any interest after expiry of the tender validity period, but not later than thirty days after conclusion of the resultant contract. Successful bidder's earnest money will be returned without any interest, after receipt of performance security from that tenderer.
6. Earnest Money is required to protect the purchaser against the risk of the Tenderer's conduct which would warrant the forfeiture of the EMD. Earnest money of a tenderer will be forfeited if the tenderer withdraws or amends its tender or impairs or derogates from the tender in any respect within the period of validity of its tender or if it comes to notice that the information/documents furnished in its tender is incorrect, false, misleading or forged without prejudice to other rights of the purchaser. The successful bidder's earnest money will be forfeited without prejudice to other rights of Purchaser if it fails to furnish the required performance security within the specified period.

VIII. TENDER VALIDITY

The contract for supply of drugs is for one year i.e. from bidders must keep the price valid for one year during the period of contract i.e. from 1st December 2020 to 30th

November 2021) and may be extended further up to three months with same rates, terms & conditions. So, rates quoted should be valid for 15 months from the closing date of the tender.

IX. TENDER OPENING

1. The Tender Inviting Authority will open the e-tenders at the specified date and time and at the specified place as indicated in the NIT. In case the specified date of tender opening falls on / is subsequently declared a holiday or closed day for

the Tender Inviting Authority, the tenders will be opened at the appointed time and place on the next working day.

2. Authorized representatives of the tenderers, who have submitted tenders on time, may attend the tender opening provided they bring with them letters of authority from the corresponding tenderers. The tender opening official(s) will prepare a list of the representatives attending the tender opening. The list will contain the representatives' names & signatures and corresponding tenderers' names and addresses.
3. This being a Two-Bid Tender system, the **Techno-Commercial Tenders** are to be opened in the first instance, at the prescribed time and date as indicated in NIT. These Tenders shall be scrutinized and evaluated by the competent committee/ authority with reference to parameters prescribed in the tender document. During the Techno-Commercial Tender opening, the tender opening official(s) will read the salient features of the tenders like brief description of the goods offered, delivery period, Earnest Money Deposit and any other special features of the tenders, as deemed fit by the tender opening official(s). Thereafter, in the second stage, the Price Tenders of only the Techno - Commercially acceptable offers (as decided in the first stage) shall be opened for further scrutiny and evaluation on a date notified after the evaluation of the Techno-Commercial tender.

X. SCRUTINY AND EVALUATION OF TENDERS

1. Basic Principle

Tenders will be evaluated on the basis of the terms & conditions already incorporated in the tender enquiry document, based on which tenders have been received and the terms, conditions etc. mentioned by the tenderers in their tenders. No new condition will be brought in while scrutinizing and evaluating the tenders.

2. Scrutiny of Tenders

- i) The Purchaser will examine the Tenders to determine whether they are complete, whether any computational errors have been made, whether required sureties have been furnished and, whether the documents uploaded are in legible form.
- ii) The Purchaser's determination of a Tender's responsiveness is to be based on the contents of the tender itself without recourse to extrinsic evidence.
- iii) The tenders will be scrutinized to determine whether they are complete and meet the essential and important requirements, conditions etc. as prescribed in the tender document. The tenders, which do not meet the basic requirements, are liable to be treated as non-responsive and will be summarily rejected.
- iv) The following are some of the important aspects, for which a tender shall be

declared non- responsive during the evaluation and will be rejected.

- (i) Tender validity is shorter than the required period.
- (ii) Required EMD or its exemption documents have not been provided.
- (iii) Tenderer has not agreed to give the required performance security of required amount in an acceptable form.
- (iv) Poor/ unsatisfactory past performance.
- (v) Tenderers who stand de-registered/banned/blacklisted by any Central Govt. Ministries/Departments/Hospitals/Institutes.
- (vi) Tenderer is not eligible as per tender conditions.
- (vii) Tenderer has not quoted for the entire quantity as specified in the List of Requirements/ BOQ for the quoted.
- (viii) Tenderer has not agreed to other essential condition(s) specially incorporated in the tender enquiry, like delivery terms, delivery schedule, terms of payment, liquidated damages clause, warranty clause, dispute resolution mechanism applicable law.

2. Minor Infirmary /Irregularity/Non-Conformity

If during the preliminary examination, the purchaser finds any minor infirmity and/or irregularity and/or non-conformity in a tender, the purchaser may waive the same provided it does not constitute any material deviation and does not have any financial impact and, also, does not prejudice or affect the ranking order of the tenders. Wherever necessary, the purchaser will convey its observation on such 'minor' issues to the tenderer by email/registered/speed post etc. asking the tenderer to respond by a specified date. If the tenderer does not reply by the specified date or gives evasive reply without clarifying the point at issue in clear terms, that tender will be liable to be rejected.

XI. AWARD OF CONTRACT:

1. The selection of the agency will be at the sole discretion of the JIPMER who reserves its right to accept or reject any or all the proposals without assigning any reason thereof.
2. The contract for supply of supply of Drugs, Disinfectant Fluids and Surgical Dressing Items to Department of Pharmacy, JIPMER, Puducherry shall be awarded to the lowest responsive bidder (basic rate + GST) for each item (i.e. L1 for each item) except as mentioned under Clause III.B and clause III.C above for certain special drugs for which the lowest bidder will be determined by the method stated therein.
3. The decision on the award of contract will be intimated to the successful bidder.

4. The annual estimate is given only as an indication. The actual quantity procured may increase or decrease. No assurance is given that the quantity stated will actually be procured.

XII. GENERAL CONDITIONS OF CONTRACT

1. Only those companies regularly maintaining enough stock and ready to supply the quoted drugs within the lead time should participate. The entire first instalment supply should be made within 45 days (55 days for narcotic drugs) from the date of issue of order and subsequent instalments will be executed only on written request from the Head, Dept. of Pharmacy. The lead time for subsequent instalments will be 45 days. At a time, only one instalment of supply will be accepted.
2. Rates should be quoted as per our specification. The contract rates should include charges for door delivery of the goods at the Dept. of Pharmacy, First Floor, Pharmacy Block, JIPMER Hospital, Puducherry-6
3. The prices quoted by the tenderer shall not, in any case, exceed the controlled price, if any, fixed by the Govt. at the time of the supply of the articles to the Institute. If the price quoted is found to be in excess of the controlled price permissible under the Drugs (Prices Control) Order, 2013, as amended from time to time, the contractor will specifically mention this fact in his tender along with reasons for having quoted such a higher price. The Purchaser at his discretion will in such cases exercise the right of revising the price at any stage so as to conform to the controlled price or the price permissible under the Drugs (Prices Control) Order, 2013. This discretion will be exercised without prejudice to any other action that may be taken against the contractor.
4. Tenders should be submitted only for the drugs etc., asked for. Substitutes/Equivalents should not be offered. In case the drug asked for is not available and if rate for any of the item not quoted the column should be left blank.
5. The successful bidder may not sublet/outsource production of drugs quoted without the prior permission of the Director.
6. Free offers by the Tenderer shall not be accepted. Tenderers desiring to offer free goods/items may reduce their rates suitably while quoting.
7. Prices quoted should be inclusive of all charges like packing, forwarding, Insurance, duties and education cess etc., However the breakup of GST have to be shown separately, which are or may become payable by the contractor under existing or future laws or rules of the country of origin/supply of delivery during the course of execution of the contract.
8. For any of the drugs which the successful bidder (L1) has failed to supply, it will be open to the Director or to any person authorized by him on his behalf to

purchase the said drug from the next lowest firm readily willing to supply or from the open market and to recover from the successful bidder (L1) the difference (Minimum Rs5000), if any, between the price of the drugs so procured and the price payable under the contract to the successful bidder (L1) had the bidder supplied the drug. The minimum penalty of Rs.5,000/- shall be levied in case of non-supply even if the drug has not been procured from an alternative source.

9. Any attempt on the part of the Tenderers or their Agents to influence the department in their favour by personal canvassing with the officers concerned will disqualify them.
10. If any product is found substandard in the terms of that product packaging and at the time of use, the whole quantity mentioned in supply order is to be replaced including consumed items without any extra cost to the hospital within 24 hours failing no payment will be made for the quantity already consumed. In addition, if replacement is not made within 24 hours, it will be open to the Director or to any person authorized by him on his behalf to purchase the said drug from the next lowest firm readily willing to supply or from the open market and to recover from the successful bidder (L1) the difference (Minimum Rs.5,000), if any, between the price of the drugs so procured and the price payable under the contract to the successful bidder (L1) had the bidder supplied the drug. The minimum penalty of Rs.5,000/- shall be levied in case the drugs are not replaced, even if the drug has not been procured from an alternative source.
11. Statutory documentation such as Sales Tax/VAT/GST etc., are the sole responsibility of the supplying agency/firm.
12. The bidder always should indemnify JIPMER against all claims, damages or compensation under various statutory provisions.
13. In case of breach of any terms and conditions of the contract, the EMD or Performance Security Deposit of the Contractor will be liable to be forfeited by JIPMER besides annulment of the contract. This shall in no way prejudice the institution's right to recover any consequential financial loss that the institution suffers, from the successful bidder from any other money due to the bidder or by any other method as available under law.
14. The rate quoted in the e-tender will be fixed for the whole contract period.

XIII. SPECIAL CONDITIONS

1. Drugs should conform to the Pharmacopoeial specification. The drugs should also comply with the standards required under rule 124 of the Drugs & Cosmetics Act 1935. Minimum content of active ingredients should not be less than the labelled amount at the time of delivery of drugs.

2. In case of Drugs with life: -
 - a) Stock should be supplied to this Institute from the latest batch and such a stock should have a minimum life period of 18 Months. Depending upon the normal potency prescribed, supplies with a minimum life period of one year at the time of receipt will be accepted and bill will be passed only for the consumed quantity after the expiry date. Drugs less than 3 months shelf life in the stock of JIPMER Pharmacy should be replaced by supplier free of cost.
 - b) In the event of such drugs not being utilized within their life period, the tenderer should undertake to replace the unexpended stock by fresh stock without any extra cost.
 - c) Tenderers should clearly mention the Brand name of the drugs, etc., offered by them in their tenders. The composition of the formulations wherever possible may be furnished.
3. The Tenderer will invariably supply with Logograms as “**JIPMER SUPPLY NOT FOR SALE**” along with Batch No., Manufacturing Date & Expiry Date of Drugs. Otherwise item will be rejected. Delaying supply due to Logograms will not be accepted.
4. **Rates quoted should be on door delivery basis on first floor of the pharmacy block. Coolie charges if any will not be borne by the institute. Coolies should be brought by the transport agencies whenever required.**
5. **Strips, tablets & ampoules of different drugs should be visibly different in colour, size and shape. If two or more drugs supplied by the tenderer in this tender look similar, the supply may not be accepted. Hence the tenderers are requested to make sure the tablets/capsules/ampoules/labels do not physically resemble each other. Failure to comply will lead to cancellation of the order and alternate procurement action will be taken and the difference in cost (minimum Rs.5000/-) will be levied as penalty.**
6. During the delivery, if it is found that the supplies do not resemble the sample carton box which were submitted and are significantly different, the supply maybe rejected and the same has to be replaced within 24 hours of the supplier being intimated about it failing which the order will be placed with the next lowest firm readily willing to supply the drug or from the open market and to recover from the successful bidder (L1) the difference (Minimum Rs.5,000), if any, between the price of the drugs so procured and the price payable under the contract to the successful bidder (L1) had the bidder supplied the drug. The tenderer who does not comply will be required to pay the difference in cost as penalty (minimum Rs.5,000/).The minimum penalty of Rs.5,000/- shall be levied in case the drugs are not replaced, even if the drug has not been procured from an alternative source.
7. Tenderers must quote only those items which correspond to the specifications prescribed in the tender with regard to composition, strength, packing, formulation and other aspects. However, in the absence of tenderers quoting the exact

specifications, the Director reserves the right to select an item that is closest to the specifications.

8. **For Renal transplant drugs mixing the brands is not advisable, hence the manufacturers are instructed to quote all Renal Transplant drug strengths (0.25mg, 0.5mg, 1 mg, and 2mg for Tacrolimus and 250 mg and 500 mg for Mycophenolate Mofetil).Quotation for only one strength will not be considered.**
9. **For Biologicals mixing the brands is not advisable and hence the manufacturers are instructed to quote for both the strengths of Biologicals (Rituximab 100 mg and Rituximab 500 mg). Quotation for only one strength will not be considered.**

SAMPLE

1. Samples for Intravenous Fluids, Surgical Items and Disinfectant Items along with the carton boxes are to be submitted to the Head, Dept. of Pharmacy, Dept. of Pharmacy, First Floor, Pharmacy Block, JIPMER, Puducherry 605006 on weekdays (Monday to Friday) between 2 P.M and 4 P.M. The messenger may request for a receipt from the person accepting the samples.
2. Samples for surgical items and disinfectant items are to be clearly labelled outside indicating the name and address of the company. A list of all the items for which samples have been sent should be enclosed in the sample package. Companies not submitting samples along with the carton boxes will not be considered and no reminder will be sent.
3. **Samples should reach Pharmacy Office within ten days of bid closing.**

SUPPLY CONDITIONS

1. Orders will be placed with the selected tender parties and payment will be made to them directly through ECS as per Government rules.
2. **The tenderer should intimate to this office about the supply position within one week from the date of supply order.** Failing which, it would be considered that the tenderer is not interested in executing the supply against the order and the purchase order will be awarded to next lowest tenderer.
3. **In case the selected company wants to supply and raise the bill through their authorized distributor, the name, address and contact telephone number should be given while submitting the tender itself. Further modifications will not be entertained during the tender period. In extraordinary situation it may be permitted after the approval from the competent authority. In such case the companies are requested to supply directly from company.**
4. Each supply and batch should be accompanied with a copy of Certificate of Analysis (COA)from Government approved drugs testing laboratory. Failure to comply may lead to rejection of supply. First supply of the item should accompany with manufacturing license/import license mentioning the name of the item supplied.

5. The strip and the package should clearly state the name of the manufacturer who has participated in the tender. Supply in loose packing is not acceptable.
6. Special drugs wherever strip packing is not available will be accepted, if provided in plastic/glass bottles.
7. The order will be awarded to the successful tenderer for the supply of Drugs for the specified period and the Tenderer shall supply on receipt of supply orders from the Officer in Charge of Purchase. A scanned copy of supply order will be sent to the e mail of the manufacturer and supplier.
8. The lead time is 45 days for General Drugs and 55 days for Narcotic Drugs.
9. **The entire first instalment should be executed within 45 days (55 days for Narcotic Drugs) from the date of issue of supply order. If the supply is not executed within 45 days, the supply order will be cancelled, and alternate procurement action will be undertaken. The difference in cost (Minimum Rs.5000) will be recovered from the defaulted supplier as penalty.**
10. **If part supply is ordered the supplier must execute the mentioned part supply at once. Split part supply is not accepted.**
11. All I.V. fluids unless otherwise indicated should be manufactured using Form Filled Seal (FFS) technology. The bottles should be well packed in sturdy boxes to withstand stacking and transport. If packing is not satisfactory and the cardboard boxes are flimsy, the supply will be rejected.
12. Bandages /POP bandages will be tested in the Institute and only those items which are found of good quality and suitable will be included for selection. No reason will be given for rejection.
13. Proper maintenance of the cold chain during transit is essential for drugs that require storage in cold room. Packages received without proper cool packs and whose temperature is not within stipulated range will be rejected.
14. Supply of IV-fluids should be in truck having fixed metallic roof to avoid damage during transit.
15. As far as possible supply should be made from single or minimum number of batches. Separate batches should be packed separately.
16. Packing slip containing full details about the contents like Quantity, Batch number, Manufacturing Date, and Expiry date should be pasted on every parcel.
17. Ampoules should be supplied with aluminium files for breaking them. Each pack should contain at least 5 files.

18. **Ampoules should be supplied in boxes with 10 Ampoules to avoid damage. Similarly, vials should be supplied as 10 to 25 Vials in a box. The boxes should be supplied with separator for each Ampoule/Vial.**
19. The company should ensure that the size of the letter font in the strips of the tablets, capsules and in the vials and ampoules of the injections should be readable and visible to enable the Pharmacists/Doctors/Patients to identify the drugs without difficulty failing which the drugs will be rejected.
20. Drugs and other items supplied to the Institute should be of good quality and the decision of the Director in this regard is final and binding on the tenderer. If the quality of the drugs is not satisfactory and they do not meet the requirements such as maintenance of proper cold chain, the same will be rejected and the supplied item has to be removed from the Institute by the tenderer or by the contractor immediately at their own expenses after receipt of intimation. If the item is not removed within **15 days** from the date of intimation letter, the supplies will not be returned to the tenderer and they will be destroyed.
21. **The company should ensure that the drugs supplied by them should be of different strip colour and size. If JIPMER receives any look alike drugs with same strip colour and size, the supply will be rejected, and alternate procurement action will be initiated. The difference in cost (Minimum Rs.5000) will be recovered from the defaulted company.**
22. Supply orders will be sent through e-mail followed with speed post. The Tenderers are requested to give their correct postal address and valid e mail-id to enable the delivery of supply orders. Further they are requested to check
The email regularly.
23. **For serial Nos. 618 to 632 (Disinfectant Fluids) and 688 to 718 (Chemicals) the supply has to accompany with MATERIAL SAFETY DATA SHEET (MSDS) containing information on physical and chemical properties of the material, potential hazards and exposure control measures, how to work safely with these materials, information on usages, storage, handling and emergency procedures relate to the hazards of the materials.**

XIV. DELIVERY CONDITION

1. The lead time will be 45days. Hence, the delivery must be completed within 45 days from date of the supply order. The lead time will be 55 days for Narcotic items.
2. At the discretion of the Director, JIPMER late delivery of a drug may be accepted after imposing a penalty at the rate of 0.2% of the Total value of the order, per day, for delayed supply subject to a maximum of 15 days for each item, beyond which it will be open to the Director or to any person authorized by him on his behalf to purchase the said drug from the next lowest firm readily willing to supply or from the open market and to recover from the successful bidder (L1) the difference (Minimum Rs.5,000), if any, between the price of the drugs so procured and the price payable under the contract to the successful bidder (L1) had the bidder supplied the drug.

Acceptance of late supply after imposing a penalty is solely at the discretion of the Director, JIPMER and does not confer any right on the successful bidder to supply the drug after the due date. The minimum penalty of Rs 5,000/- shall be levied in case of non-supply, even if the drug has not been procured from an alternative source.

3. Each carton should contain only ONE drug belonging to one batch only and each drug should be packed separately. Supplies with two or more drugs packed in a single pack to save space will not be accepted.
4. The drugs and other items should be properly packed to avoid damage/shortage during transit. Damages/shortages if any found on opening the case will be reported to the supplier immediately and the same should be replaced at the supplier's own cost. No insurance cost charges are payable.
5. Labelling on vials/ampoules/I.V. fluids and other items should be clear and legible. Labels should be well stuck to the container. If not, the supply may be rejected.
6. The name, designation , proper address, land line phone numbers, mobile numbers, fax numbers, email IDs of the contact person(s) as well as the local dealer/distributor should be clearly mentioned in a separate sheet and any change of phone numbers should be notified. The above details should be emailed to pharmacy at jipmer.pharmacy@gmail.com.
7. Supplies should be marked to Head, Dept. of Pharmacy, First floor, Pharmacy Block, JIPMER, Puducherry 605006, and should be door delivered to the first floor of Pharmacy. Supplies sent on 'to-pay' basis will not be accepted. Coolie charges if any will not be borne by the Institute. Coolies should be brought by the transport agencies/Supplier whenever required.

XV. PACKAGING

1. The Drugs and medicines shall be supplied in the package specification and the package shall carry the logograms specified as **“JIPMER SUPPLY NOT FOR SALE”**
2. The packing in each carton shall be strictly as per the specification mentioned below. The outer carton should be of white board with a minimum of 300 GSM with laminated packing for the strips, blisters, ointments, creams etc. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties.
3. No corrugated package should weigh more than 15 kgs (product + inner carton+ corrugated box). All corrugated boxes should be of 'A' grade virgin paper. All drugs should be packed in first-hand boxes only.
4. The corrugated boxes should be narrow flute. Every box should be preferably single joint and not more than two joints. Every box should be stitched using pairs of metal pins with an interval of two inches between each pair. The boxes should be stitched and not joined using calico at the corners.

5. The flaps should uniformly meet but should not overlap each other. The flap when turned by 35-60 degrees should not crack. Every box should be sealed with gum tape running along the top.
6. The strength of the cardboard boxes should withstand the stacking up to 5 levels.
7. Every box should be strapped with two parallel nylon carry straps (they should intersect).
8. **The labels in the case of injectable should clearly indicate whether the preparations are meant for Intravenous (IV), Intramuscular (IM), Subcutaneous (SC), etc.**
9. It should be ensured that only first-hand fresh packaging material of uniform size including bottle and vial is used for packing.
10. All primary packing containers should be strictly conforming to the specification included in the relevant pharmacopoeia. Packing should be able to prevent damage or deterioration during transit.
11. In the event of items of drugs supplied found to be not as per specifications in respect of their packing, the Tender Inviting Authority is at liberty to make alternate purchase of the item of drugs and medicines for which the Purchase orders have been placed from any other sources or in the open market or from any other bidder who might have quoted higher rates at the risk and the cost of the supplier and in such cases the tender inviting authority has every right to recover the cost and impose difference in cost as penalty.

OTHER CONDITIONS

1. The Director reserves the right to reject the tenders and the supply of all the items or of only one or more of the items tendered for, in a tender without assigning any reason for doing so.
2. The Director will be at liberty to terminate, without assigning any reason the Contract either wholly or in part on One Month's Notice. The Tenderer will not be entitled to any compensation whatsoever in respect of such termination. The contracts shall also be renewed for a further period beyond the contract time in cases where such renewal is necessary.
3. If any of the drugs which the tenderer has failed to supply, it will be open to the Director or to any person authorized by him on his behalf to purchase the said articles and to recover from the Tenderer the difference (Minimum **Rs.5000**), if any, between the price of the Drugs and the price payable under the contract to the Tenderer. Or the amount of EMD will be forfeited

4. Any attempt on the part of the Tenderers or their Agents to influence the department in their favour by personal canvassing with the officers concerned will disqualify them.

5. E mail/Hard copy quotations will not be considered.

6. SELECTION OF TENDERS WOULD VERY MUCH DEPEND UPON THE LOWEST NET RATE(BASIC PRICE + GST). HOWEVER, PURCHASE PREFERENCE AS PER GOVERNMENT OF INDIA ORDERS WILL BE GIVEN IN CERTAIN CASES AS ELABORATED BELOW.

7. PURCHASE PREFERENCE

- a. The Procurement of goods and services under this e-tender will be regulated as per the applicable provision of Public Procurement (Preference to Make in India), order 2017 of MoC and I (DIPP), Govt. Of India, Order No.P-45021/2/2017-B.E.-II dated 15.6.2017 as further amended by Order No.P-45021/2/2017-B.E.-II dated 28.05.2018, Order No.P-45021/2/2017-B.E.-II dated 29.05.2019, and Order No. P-45021/2/2017-PP (BE-II) dated 04.06.2020. Therefore, bidders who are claiming to be regulated under the said order are to submit a certificate in format given in Appendix- A along with documentary evidence in support of their claim wherever necessary.
- b. The Purchaser reserves the right to give the purchase preference to small-scale sectors, Micro and small scale enterprises etc. as per the instruction in vogue while evaluating, comparing and ranking the responsive Tenders as given in the MSMED Act 2006 reproduced below:
- c. In exercise of powers conferred in Section 11 of the Micro, Small and Medium Enterprises Development (MSMED) Act 2006, the Government has notified a new Public Procurement Policy for Micro & Small Enterprises effective from 1st April 2012. The policy mandates that 25% of procurement of annual requirement of goods and services by all Central Ministries/Public Sector Undertakings will be from the micro and small enterprises. The Government has also earmarked a sub-target of 4% procurement of goods & services from MSEs owned by SC/ST entrepreneurs out of above said 25% quantity.
- d. In accordance with the above said notification, the participating Micro and Small Enterprises (MSEs) in a tender, quoting price within the band of L1+15% would also be allowed to supply a portion of the requirement by bringing down their price to the L1 price, in a situation where L1 price is from someone other than an MSE. Such MSEs would be allowed to supply up to 25% of the total tendered value. In case there are more than one such eligible MSE, the 25% supply will be shared equally. Out of 25% of the quantity earmarked for supply from MSEs, 5% quantity is earmarked for procurement from MSEs owned by SC/ST entrepreneurs. However, in the event of failure of such MSEs to participate in the Tender process or meet the tender

requirements and the L1 price, the 5% quantity earmarked for MSEs owned by SC/ST entrepreneurs will be met from other participating MSEs.

- e. The MSEs fulfilling the prescribed eligibility criteria and participating in the Tender shall enclose with their tender a copy of their valid registration certificate with District Industries Centres or Khadi and Village Industries Commission or Khadi and Village Industries Board or Coir Board or National Small Industries Corporation or any other body specified by Ministry of Micro and Small enterprises in support of their being an MSE, failing which their tender will be liable to be ignored.
 - f. Special provision for Micro and Small Enterprise owned by women: – Out of the total annual procurement from Micro and Small Enterprises, 3 per cent from within the 25 per cent target shall be earmarked for procurement from Micro and Small Enterprises owned by women.
 - g. Note: “If the bidder is a MSME, it shall declare in the bid document the Udyog Aadhar Memorandum Number issued to it under the MSMED Act, 2006. If a MSME bidder do not furnish the UAM Number along with bid documents, such MSME unit will not be eligible for the benefits available under Public Procurement Policy for MSEs Order 2012.
8. The validity of tender may be extended, if necessary, at the discretion of the Director.
9. . Intending tenderers should submit the tender through online in prescribed for On or before the last date. Submission of Online Tender should be well in advance to avoid any problem at the eleventh hour.

XVI. QUALITY

1. **Drugs etc. supplied to the Institute should be of good quality and the decision of the Director in this regard is final and binding on the Tenderer. If the quality of drugs is not satisfactory and do not meet the Pharmacopoeial requirements and proper maintenance of cold chain, the same will be rejected and the supplied item has to be removed from the Institute by the Tenderer or by the supplier immediately at their own expenses after receipt of intimation. If the item is not removed within 15 days from the date of the intimation letter, the supplies will be destroyed. The drugs will not be returned to the tenderer and no claim will be entertained.**
2. **Each batch of supply should be accompanied with the copy of Certificate of Analysis (COA) from the Government approved drug testing laboratories as per CDSCO refer : www.cdsc0.nic.in/list of approved laboratories**
3. **Supplies without the Certificate of Analysis from the government approved drug testing laboratories will not be accepted under any circumstances and it will be treated as rejected.**

4. If the quality of the drug is found to be not conforming to the prescribed quality level in the quality control test by Drug analysis Laboratory of JIPMER, the supply/consignment will be rejected.
5. If any written complaints received from the user departments regarding the quality of drugs, the whole quantity mentioned in supply order is to be replaced including consumed items without any extra cost to the hospital within 24 hours failing no payment will be made for the quantity already consumed. In addition, if replacement is not made within 24 hours, it will be open to the Director or to any person authorized by him on his behalf to purchase the said drug from the next lowest firm readily willing to supply or from the open market and to recover from the successful bidder (L1) the difference (Minimum Rs.5,000), if any, between the price of the drugs so procured and the price payable under the contract to the successful bidder (L1) had the bidder supplied the drug. The minimum penalty of Rs 5,000/- shall be levied in case of non-supply. even if the drug has not been procured from an alternative source.
6. If the quality of the drugs found to be not of standard quality, the random Samples of the batch will be tested by our in-house Drug Analysis Laboratory and it will be compared with COA submitted by the company. Action will be taken accordingly.
7. **In case of poor quality of items supplied, the name of the tenderer as well as the details of quality control failure will be displayed on the web page of JIPMER**
8. **The quality issues will be intimated to CDSCO, DCGI, TNMSC and similar procurement agencies.**

XVII. PENALTY

1. **If the successful bidder fails to supply the ordered quantity of drugs within the lead time of 45 days (55 days for narcotic drugs) from the date of issue of the order, the order will be cancelled and the alternate procurement action will be taken and the difference in cost (Minimum Rs.5000/-) will be recovered as penalty by way of adjustment against the Tenderer's pending bills or performance security. In addition, any shortfall will also be recovered from the successful bidder by taking recourse to such action as permitted under law. The Risk purchase penalty (difference in cost) will be recovered from L1 firm only.**

XVIII. FORCE MAJEURE

1. Force Majeure (FM) means extraordinary events or circumstance beyond Human control such as an event described as an Act of God (like a natural calamity) or events such as war, strike, riots, crimes (but not including negligence or wrong-doing, predictable/seasonal rain and any other events specifically excluded in the clause). An FM clause in the contract frees both parties from contractual liability and obligation when prevented by such events from fulfilling their obligations under the contract.
2. An FM clause does not excuse a party's non-performance entirely, but only suspends it for the duration of the FM. The firm has to give notice of FM as soon as it occurs, and

it cannot be claimed ex-post facto. There may be a FM situation affecting the purchase organization only. In such a situation, the purchase organization is to communicate with the supplier along similar lines as above for further necessary action. If the performance in whole or in part or any obligation under this contract is prevented or delayed by any reason of FM for a period exceeding 90 (Ninety) days, either party may at its option terminate the contract without any financial repercussion on either side.

3. Notwithstanding the punitive provisions contained in the contract for delay or breach of contract, the supplier would not be liable for imposition of any such sanction so long as the delay and/or failure of the supplier in fulfilling its obligations under the contract is the result of an event covered in the FM clause.

XIX. BLACKLISTING

- 1. If the tenderer(s) fail(s) to supply two or more times within the stipulated period of 45 days (55 days for narcotic drugs) during the tender period, the EMD of the tenderer(s) is liable to be forfeited to the institution, in addition to the recovery of penalty involved for the above purchase.**
- 2. Further, the tenderer will also be liable to be blacklisted for 3 years to trade with this institute. Details of tenderers blacklisted by the institute will be put up in the institute website. The same will be informed to similar government procurement agencies.**
- 3. Any violation of tender norms may lead to blacklisting of the tenderer by the Institute initially for one year and followed by 3 years.**

XX. REQUIREMENT OF GODOWN SPACE

For the Drugs which will have one Truck load or more per supply, the supplier, at his own expense, should provide Godown Space outside JIPMER to enable the supplies to the institute within seven days. The drugs for which the supplies will be a truck load are given below.

| S. No | Nomenclature |
|-------|--|
| 535 | Compound Sodium lactate (Ringer lactate solution for injection) 500 ml Bottle FFS pack |
| 536 | Dextrose Injection 5% 500 ml Bottle FFS pack |
| 546 | Sodium chloride injection 0.9% 100 ml Bottle FFS pack |
| 547 | Sodium chloride injection 0.9% 500 ml Bottle FFS pack |
| 549 | Compound Sodium lactate (Ringer lactate solution for injection) 500 ml in collapsible /flexible bags |
| 550 | Continuous ambulatory dialysis fluid 1.5% (with asymmetric Y) 2 ltrs Bag with minicap |

| | |
|-----|--|
| 551 | Continuous ambulatory dialysis fluid 2.5% (with asymmetric Y) 2 ltrs Bag with minicap |
| 552 | Continuous ambulatory dialysis fluid 4.25% (with asymmetric Y) 2 ltrs Bag with minicap |
| 559 | Sodium chloride injection 0.9% 500 ml in collapsible/flexible bags |
| 639 | Handloom cotton gauze absorbent 50cm x 20 mtrs with min. wt. of 250 gm packet as per schedule F(II) of Drug and cosmetics Act 1940 |
| 648 | Wool cotton absorbent IP in packet of 500gm Net wt. |

XXI. POINTS TO REMEMBER

1. Listing of serial number of Drugs should follow the same serial order as in Tender Schedule.
2. Rate quoted should be F.O.R at First floor, Pharmacy Block, JIPMER, Puducherry -6.
3. Tenderers should quote final rates. No discount/free goods/additives will be accepted.
4. Rates should be according to unit asked for. Specification & packing size of each product should be as per details given in the tender.
5. Plea of clerical error, typographic error etc. committed by tenderer will not be accepted, unless intimated prior to opening of price bid. No correspondence will be entertained after opening the price bid.
6. The rates quoted by the tenderers shall not in any case exceed the controlled Price fixed by schedule I of Drugs (Price Control Order) Amendment 2013.
7. If a tenderer quotes a rate higher than the controlled rate, the Tenderer will be rejected and prevented from participating in the tender for the next three years.
8. The rates quoted should be in Indian currency only. Tenders in any other currency are liable to be rejected.
9. If the rate for any item is not quoted, the price column should be left blank.
10. Participation in the tender implies that the participant is accepting all terms and conditions of the tender.

XXII. Liquidated damages:

Supplies made after the stipulated period may be accepted if required, by levying a penalty at the rate of 0.2% of the Total value of the order per day, for a maximum of 15 days. However, the decision is purely on the discretion of the Director, JIPMER.

XXIII. Risk Clause:

The contractor shall at all times have standby arrangements for carrying out the work under the contract, in case of any failure of the existing arrangements. JIPMER reserves the right for termination of the contract at any time by giving 30 days written notice, if the services are found unsatisfactory and also has the right to award the contract to any other selected bidders at the cost, risk and responsibilities of contractor and excess expenditure incurred on account of this will be recovered by JIPMER from the contractor's Security Deposit or pending bills or by raising a separate claim. During the notice period the supplier shall continue the supply.

1. All necessary reports and other information will be supplied on a mutually agreed basis and regular meetings will be held with the department.
2. In the event of loss/damage of the item at the premises of the department, premises due to negligence/carelessness of contractor staff, then the contractor shall compensate the loss to JIPMER.

XXIV. Termination clause:

During the period of agreement if it is found that the agency is not providing proper services, the JIPMER reserves rights to make the vendor forfeit the performance security deposit deposited with JIPMER or part thereof in favour of JIPMER and agreement will be terminated after giving 30 days' notice. Furthermore, in such situations, tender can be allotted to next lowest bidder readily willing to supply the item or from the open market and the difference in cost shall be recovered from the successful bidder who is in breach of the contract. In addition in case it is found that the supplier is charging by fraudulent means or indulging in criminal activities the contract will be terminated immediately and action will be taken against the bidder as per the conditions in this tender besides other provisions of the law.

XXV. Jurisdiction of the courts

Jurisdiction for the settlements of disputes if any is Puducherry only.

In above mentioned conditions Director JIPMER reserves all the rights

Officer-in-Charge
Purchase Section
For
Director, JIPMER, Puducherry – 6

Annexure 1

TENDER FORM
(On Firms' Letter Head)

To,
The Director
JIPMER, Puducherry 605006

Date _____

Ref. Your Tender Document No. _____ dated _____

We, the undersigned have examined the above mentioned Tender document No. ____ dated ____, including amendment/corrigendum No. _____, dated _____(if any), the receipt of which is hereby confirmed. We now offer to supply and deliver _____(Description of goods and services) in conformity with your above referred document **for the sum as shown in the price schedules attached herewith and made part of this tender**. If our tender is accepted, we undertake to supply the goods and perform the services as mentioned above, in accordance with the delivery schedule specified in the tender document.

We have read the clauses regarding restrictions on procurement from a bidder of a country which shares a land border with India and on sub-contracting to contractors from such countries and we certify that this bidder is not from such a country/ from such a country and has been registered with the Competent Authority and a copy of the valid registration by the Competent Authority is attached as evidence of the same (Strike out the portion not applicable). We hereby certify that this bidder fulfils all requirements in this regard and is eligible to be considered. If there are any Turnkey works involving possibility of sub-contracting the bidder will not sub-contract any work to a contractor from such countries unless such contractor is registered with the Competent Authority. I hereby certify that this bidder fulfils all requirements in this regard and is eligible to be considered.

We further confirm that, if our tender is accepted, we shall provide you with a performance security of required amount in an acceptable form in terms of Clause IV "Instructions to Bidders" Sub-Clause 6 in the tender document, for due performance of the contract.

In case we have uploaded the same receipts for Tender Fee and EMD that we paid for the tender No.Pur.8 (1)/2020-21/TENDER-I dated 10-06-2020 and its subsequent amendments that has now been cancelled, we agree to the adjustment of those payments against corresponding payments required for participation in this tender and bind ourselves to the terms and conditions related to these payments as contained in this tender and shall not claim a refund of the same against the cancelled tender referred to above.

We agree to keep our tender valid for acceptance as required in Clause VIII "Tender Validity" in the Tender document or for subsequently extended period, if any, agreed to by us. We also accordingly confirm to abide by this tender up to the aforesaid period and this tender may be accepted any time before the expiry of the aforesaid period. We further

confirm that, until a formal contract is executed, this tender read with your written acceptance thereof within the aforesaid period shall constitute a binding contract between us.

We further understand that you are not bound to accept the lowest or any tender you may receive against your above-referred tender enquiry.

We confirm that we fully agree to the terms and conditions specified in above mentioned TE document, including amendment/ corrigendum if any.

(Signature with date)

(Name and designation)

Duly authorized to sign tender for and on behalf of

(Name of the firm)

Annexure 2

DECLARATION OF THE BIDDER

(To submitted on the firm's letterhead)

| | | |
|---|---|--------------------------------|
| 1. | Name & Designation of the contact person with signature | |
| 2. | Name and Address of the Tenderer | |
| 3. | Phone No a) Land line number (functional between 9 am and 5pm) | |
| 4. | Mobile No of contact person (available from 9am to 6pm) | |
| 5. | Fax No of the Tenderer | |
| 6. | Email ID of the Tenderer | |
| 7. | Email ID of the contact person | |
| 8. | Local supplier/Distributor in Chennai/ Puducherry or any other place (complete address must be written) | |
| 9. | Drug manufacturing or Import license copy to be enclosed. | |
| 10 | Whether Tenderer is registered MSE Manufacture the product quoted. (If registered MSE, submit copy of the Udyog Aadhaar certificate or Equivalent Certificate) | Yes / No |
| If there is any change in the above details, I will immediately intimate you by speed post or fax or email | | |
| I hereby declare that the details given above are true to the best of my knowledge and I have thoroughly read and understood the terms & conditions of the tender and shall abide by the rules. | | |
| | | Signature |
| Dated: | | (Name with designation & seal) |

NB: This declaration form must be duly filled in by an authorized person not below the rank of Manager

CHECK LIST

| S. No | Name of the document (All documents including this check list must be signed, stamped, scanned and uploaded) | Page No |
|-------|---|---------|
| 1 | Documentary evidence for the constitution of company Like Article of Association | |
| 2 | Copy of GST registration certificate | |
| | Copy of PAN card | |
| 3 | Copy of the Manufacturing License/Import License renewed under Drugs and Cosmetics Act 1940 with approved list of Drugs under the license. Copy of certificate empanelment by the competent authority under GFR 144(xi) where applicable. (Bidder must go through GFR 144 (xi) in this regard and satisfy himself whether the rule is applicable to him or not) | |
| 4 | Non- Blacklisted certificate – Notarized affidavit | |
| 5 | Non- Conviction Certificate – from State Drug Controller | |
| 6 | GMP Certificate | |
| 7 | Market Standing Certificate for three years up to March 2020- from State Drug Controller | |
| 8 | Annual turnover statement of Rs.50 crores for any one year.e2018-19or 2017-18 certified by Auditor/Chartered Accountant. | |
| 9 | Copies of abridged Annual Auditor’s report of last 03 years (Income tax return acknowledgement, Assets and Liabilities, Balance sheet and Profit &Loss Account) . | |
| 10 | <u>Documents for Renal Transplant drugs</u> a. Market standing certificate / certificate for handling API b. Utilization certificate from the Head of the Dept. of Nephrology. | |
| 11 | Tender Form as in Annexure 1 and Declaration of the bidder as in Annexure 2 duly filled, signed in full and stamped. | |
| 12 | Tender signing authority issued by competent authority in favour of the person who is digitally signing/uploading the tender | |
| 13 | Other Documents if any | |
| 14 | Checklist | |

I/We certify that the information furnished above is true and correct. The terms and conditions are acceptable to us and have the authority to bid a tender.

Signature of the
Owner/Managing
Partner/Director

Date:
Place:

Name:
Seal :

Appendix- A

Self-certification format for claiming purchase preference under the “Public Procurement preference to Make in India” order

As per the order issued by

(i) Department of Industrial Policy and Promotion (DIPP) vide No. P-45021/2/2017-BE-II dated 15.06.2017 as further amended by Order No.P-45021/2/2017-B.E.-II dated 28.05.2018, Order No.P-45021/2/2017-B.E.-II dated 29.05.2019, and Order No. P-45021/2/2017-PP (BE-II) dated 04.06.2020; and

(ii) Department of Pharmaceuticals vide No. F- 31026/36/2016-MD dated 18.05.2018 and the subsequent orders thereof; The purchaser reserves the right to give preference to the local supplier.

A local supplier (definition of ‘local supplier’ is given in clause 2 of the aforesaid order of DIPP as amended from time to time) has to submit the following along with their e-tender(s) failing which their bid will be evaluated without considering such preference mentioned in the DIPP order dated 15.06.2017 further amended on 28.05.2018, 25.09.2019 and 04.06.2020:

a. The local supplier at the time of e-tender, bidding or solicitation shall be required to provide self-certification that the item offered meets the minimum local content and shall give details of the location(s) at which the local value addition is made in the format given below:

| “Certified that the following items quoted has more than 50% or 20% to 50% of value | | |
|---|------------------|--|
| Sl. No | Name of the item | Details of the location(s) at which the local value addition was made. |
| | | |
| | | |
| | | |

Authorized Signature:
Name:
Designation:

b. In cases of procurement for a value in excess of Rs. 10 Crore. the local supplier shall be required to provide a certificate from the statutory auditor or cost auditor of the company (in the case of companies) or from a practicing cost accountant or practicing chartered accountant (in respect of suppliers other than companies) giving the percentage of local content.

- c. Minimum Local Content: 'Class-I local supplier' means a supplier or service provider, whose goods, services or works offered for procurement, has local content equal to or more than 50%, as defined under the Order. 'Class-II local supplier' means a supplier or service provider, whose goods, services or works offered for procurement, has local content more than 20% but less than 50%, as defined under this Order.
- d. Margin of Purchase Preference: The margin of purchase preference shall be 20%.
- e. Manufacture under license/technology collaboration agreements with phased indigenization are exempted from meeting the stipulated local content if the product is being manufactured in India under a license from a foreign manufacturer who holds intellectual property rights and where there is a technology collaboration agreement/transfer of technology agreement for indigenous manufacture of a product developed abroad with clear phasing of increase in local content
- f. Decisions on complaints relating to implementation of this Order shall be taken by the competent authority which is empowered to look into procurement-related complaints relating the procuring entity.
- g. A constituted committee with internal and external experts will examine for independent verification of self-declarations and auditor's/accountant's certificates on random basis and in the case of complaints.
- h. A fees of **Rs.10000/-** in the form of demand draft favouring The Director, JIPMER, payable at Puducherry, is required to be deposited with complaints for verification of local content.
- i. False declarations will be breach of the Code of Integrity under Rule 175(1)(i)(h) of the General Financial Rules for which a bidder or its successors can be debarred for up to two years as per Rule 151(iii) of the General Financial Rules along with such other actions as may be permissible under law.
- j. A supplier who has been debarred by any procuring entity for violation of this Order shall not be eligible for preference under this Order for procurement by any other procuring entity for the duration of the debarment. The debarment for such other procuring entities shall take effect prospectively from the date on which it comes to the notice of other procurement entities.